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ABSTRACT 
Controls in Member States have revealed the presence of phenylbutazone in horse carcasses intended for the 
food chain.  Following the request from the European Commission, the European Medicines Agency and the 
European Food Safety Authority jointly concluded on the risk assessment on residues of phenylbutazone in 
horse meat in the context of recent fraudulent practices. The Committee for Veterinary Medicinal Products 
assessed the consumer safety for phenylbutazone in 1997 and identified the main risks for the consumer as 
idiosyncratic
4  blood dyscrasias and the genotoxic/carcinogenic potential for which no thresholds could be 
identified and no maximum residue limits could be established. The substance can therefore not be used in 
animals destined to enter the food chain.  These main risks have been re-confirmed in the present statement as no 
new relevant information has become available since the initial safety assessment. Exposure to phenylbutazone 
from horse meat consumed as such or present  in beef-based products was assessed on the basis of limited 
monitoring data provided by 19 Member States and  of  conservative assumptions. Up to 144 and up to 
36 800 individuals per 100 million could be potentially exposed across countries and age groups each day. On a 
given  day,  the  probability  of  a  consumer  being  both  susceptible  to  developing  aplastic  anaemia and  being 
exposed to phenylbutazone was estimated to range approximately from 2 in a trillion to 1 in 100 million. The 
risk of carcinogenicity to humans from exposure was considered very low based on the available experimental 
data on organ toxicity and carcinogenicity, as well as on the low exposure levels and the infrequent exposure to 
phenylbutazone from horse meat or adulterated beef-based products.  Measures proposed to further minimise the 
risk include strengthening of the horse passport system, harmonised monitoring of phenylbutazone and its main 
metabolite and better reporting of monitoring of veterinary drug residues and other substances across the EU. 
© European Food Safety Authority, European Medicines Agency, 2013 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Phenylbutazone  (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione)  is  a  non-steroidal  anti-inflammatory 
drug (NSAID) for the short-term treatment of pain and fever in animals.  
Phenylbutazone is not authorised for use in food-producing animals as maximum residue limits are not 
established for the substance. In the EU several human medicinal products with the pharmacological 
substance phenylbutazone have a marketing authorisation.  
Controls in Member States have revealed the presence of residues of phenylbutazone in horse meat 
which indicate an illegal use of carcasses of horses treated with this pharmacological substance.  
The presence of residues of phenylbutazone in horse meat prompted the competent authorities to take 
appropriate and proportionate actions as laid down in Directive 96/23/EC. These include, amongst 
others, restrictions on movement of animals and obligatory testing of the remaining animals. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The  European  Commission  asks  the  European  Food  Safety  Agency  and  the  European  Medicines 
Agency for a joint statement on the presence of residues of phenylbutazone in horse meat.  
The Agencies shall perform a risk assessment on residues of phenylbutazone in horse meat.  
The statement shall provide advice on any potential risk posed to consumers from the presence of 
residues of phenylbutazone in horse meat. In evaluating the matter, the agencies should consider both 
the  risk  posed  from  direct  consumption  of  horse  meat  and  the  risk  from  other  products  illegally 
contaminated with such food.  
The joint statement should identify, where appropriate, if additional control options are needed to 
minimise the risks identified. 
APPROACH TAKEN TO ANSWER THE TERMS OF REFERENCE 
European Medicines Agency (EMA) and European Food Safety Authority (EFSA) set up a joint ad-
hoc  expert  group  for  the  preparation  of  the  Scientific  output.  Experts  from  the  EFSA  Panel  on 
Contaminants in the Food Chain, experts on safety from the EMA Committee for Medicinal Products 
for Veterinary Use (CVMP) and the EMA Committee for Medicinal Products for Human Use (CHMP) 
were  nominated  as  members  of  the  joint  expert  group.  EFSA  was  responsible  for  the  exposure 
assessment and EMA  was responsible  for the safety assessment. The  overall risk assessment  was 
finalised  by  the  full  group  of  experts.  The  statement  was  reviewed  by  two  external  reviewers 
nominated by EFSA and was adopted by the CVMP on 11 April 2013. Phenylbutazone in horse meat  
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ASSESSMENT 
 
1.  Introduction 
The  present  statement,  jointly  prepared  by  the  European  Food  Safety  Authority  (EFSA)  and  the 
European Medicines Agency (EMA), deals with the risk assessment on the presence of residues of 
phenylbutazone in horse meat in relation to the presence of residues of phenylbutazone in horse meat 
reported by several Member States, indicating an illegal use of carcasses of horses treated with this 
pharmacological substance.  
Phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione) is a synthetic pyrazolone derivative with 
anti-inflammatory,  antipyretic  and  analgesic  properties  (non-steroidal  anti-inflammatory  drug 
(NSAID)). 
In veterinary medicine, phenylbutazone is not authorised for use in food-producing animals in the 
European  Union  (EU)  following  the  evaluation  by  the  Committee  for  Medicinal  Products  for 
Veterinary  Use  (CVMP)  in  1997  (see  Appendix  A  CVMP  Summary  Report).  However, 
phenylbutazone is used to treat musculoskeletal disorders, such as rheumatoid and arthritic diseases 
and for pain relief in  non-food producing animals including  horses  not destined to  enter the food 
chain.  
The presence of residues of phenylbutazone in horses being sent for slaughter indicates the presence of 
illegal practices, possibly occurring to facilitate the disposal of animals not intended to enter the food 
chain.  In  the  EU,  horses  are  subjected  to  a  specific  traceability  system  and  since  2000,  they  are 
identified by a life-time  identification  document,  named passport in accordance  with Commission 
Regulation (EC) No 504/2008
5. Horse passport is a major element of the Food Chain Information 
(FCI) and the presence of illicit practices possibly including falsification of passports may then resu lt 
in animals which have been treated with drugs not approved for food -producing animals, such as 
phenylbutazone, entering the food chain.  
The main strengths and weaknesses of the current horse identification and FCI systems will be 
addressed in further detail in the EFSA Scientific Opinion on public health hazards to be covered by 
inspection of meat (solipeds) scheduled to be published by June 2013.  
In human medicine, phenylbutazone is authorised for use in the treatment of severe cases of chronic 
inflammatory diseases (e.g. reumathoid arthritis, arthritis urica, spondolytitis) where a satisfactory 
effect cannot be achieved with other NSAIDs. The therapeutic doses  typically range from 200 to 
600 mg/person per day. Phenylbutazone is approved in some European Union (EU) countries only as a 
second line treatment with restricted use, due to its potential serious side effects. 
2.  Hazard identification and characterisation 
Phenylbutazone  is  a  NSAID,  classified  as  an  enolic  acid,  which  exerts  its  pharmacological  and 
toxicological  effects  through  inhibition  of  the  prostaglandin  endoperoxide  synthetase  system.  The 
substance has been evaluated by the CVMP in 1997 with regard to safety of residues to the consumer.  
Following a request from the European Commission dated 28 February 2013 for an evaluation of risks 
to the consumer related to the presence of phenylbutazone residues in horse meat and in meat products 
contaminated with horse meat, experts from EMA and EFSA reviewed the main conclusions of the 
CVMP from 1997 regarding safety in the light of any new information that has become available. 
                                                   
5  Commission Regulation (EC) No 504/2008 of 6 June 2008 implementing Council Directives 90/426/EEC and 90/427/EEC 
as regards methods for the identification of equidae. OJ L 149, 7.6.2008, p. 3-32. Phenylbutazone in horse meat  
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EFSA and EMA based their evaluation related to the safety of phenylbutazone on previous evaluations 
and additional literature that became available since then. 
2.1.  Safety assessment 
The EU requires by law that foodstuffs, such as meat, milk or eggs, obtained from animals treated with 
veterinary medicines used in animal husbandry must not contain any residue that might represent a 
hazard to the health of the consumer.  Before a veterinary medicine intended for use in food-producing 
animals can be authorised in the EU, the safety of its pharmacologically active substances and their 
residues must be evaluated. This assessment is carried out by the CVMP and it is based on identifying 
an acceptable daily intake (ADI) of residues which is calculated from the concentration level at which 
no  toxic  effects  were  observed,  the  no-observed-effect  level  (NOEL),  and  applying  relevant 
uncertainty factors.  
In 1997, the CVMP has assessed the consumer safety of phenylbutazone and concluded that no ADI 
could be established (See Annex A CVMP Summary Report). The main areas of concern identified in 
relation to the substance were the lack of a NOEL for blood dyscrasias in humans, inadequate in vivo 
studies  on  mutagenicity  while some  evidence  of  genotoxic potential had been shown  in vitro, no 
NOEL  for  neoplastic  effects  in  mice  and  rats and  inadequate  data  on  reproductive  toxicity.  As  a 
consequence it was not possible to set maximum residue limits (MRLs) for phenylbutazone and thus 
its use in food-producing species is not permitted.  
The  CVMP  (1997)  noted  that  phenylbutazone  is  metabolised  to  oxyphenbutazone  and 
γ-hydroxyphenylbutazones possibly representing the major metabolic pathways in most species. The 
CVMP also noted that it was unclear whether phenylbutazone or its metabolite oxyphenbutazone was 
the more potent substance in terms of pharmacological effects and toxicity to laboratory animals due 
to the limited data available.  
Very limited information has become available since the evaluation carried out by the CVMP in 1997.  
Limited additional information on pharmacokinetics data in horses was considered which indicates 
that phenylbutazone follows zero-order kinetics where longer elimination half-lives are observed as 
the doses increase.  Administration of phenylbutazone in a horse every 24 hours for 5 consecutive 
days also indicated an increase of oxyphenbutazone during the 5-day dosing period. 
2.1.1.  Blood dyscrasias in humans 
The 1997 CVMP summary report noted that the most critical known effects in humans treated with 
phenylbutazone are blood dyscrasias, including agranulocytosis and aplastic anaemia. The myelotoxic 
effects of phenylbutazone (including its metabolites) are analogous to chloramphenicol and cytotoxic 
drugs. Mortality from fatal bone marrow depression due to phenylbutazone and oxyphenbutazone is 
estimated at 2.2 and 3.8 per 100 000, respectively, compared to 2.5-5 per 100 000 for chloramphenicol. 
The CVMP concluded that the clinical profile of phenylbutazone-induced dyscrasias is complicated as 
no  mechanism  for  phenylbutazone-induced  myeolotoxicity  in  humans  has  been  demonstrated. 
Moreover,  it  was  considered  difficult  to  relate  the  findings  of  the  in  vitro  studies  to  the  events 
observed in treated human patients and no animal model exists for the myelotoxic effects. No NOEL 
could be determined for this effect. 
Aplastic anaemia is a rare (approximately 1:30 000 cases), but life-threatening condition and has been 
reported  in  human  patients  following  therapeutic  use  of  phenylbutazone  (therapeutic  doses  range 
typically from 200 to 600 mg/person per day). At population level, a study published in JAMA (1986) 
concluded that significant excess risk estimates were found for phenylbutazone and oxyphenbutazone 
(6.6 cases per million) when used any time in a 5-month period before hospital admission. There was 
also  a  suggestion,  with  limited  numbers,  that  the  risk  was  higher  if  either  phenylbutazone  or 
oxyphenbutazone was taken regularly and for a sustained period. The risk to agranulocytosis was also 
increased (0.2 cases per million) in relation to exposure 7 days prior to the event.  Phenylbutazone in horse meat  
 
EFSA Journal 2013;11(4):3190  7 
No new relevant data became available since the CVMP evaluation in 1997 and the mechanism for the 
apparent myelotoxicity of phenylbutazone in humans is still unknown. 
It is therefore concluded that, given that a threshold level cannot be identified for the idiosyncratic 
reactions observed in humans, it cannot be excluded that a single exposure to therapeutic doses of 
phenylbutazone may cause aplastic anaemia. 
2.1.2.  Mutagenicity and genotoxicity 
In the 1997 CVMP report several in vitro studies were assessed. Tests performed for gene mutation in 
Salmonella typhimurium strains resulted in negative outcomes. Negative findings were also found in 
silkworms  but  positive  responses  were  observed  in  mouse  cells.  Several  chromosomal  aberration 
studies  using  hamster  cells  showed  a  significant  increase  in  aberrations  but  only  after  metabolic 
activation, and negative results were observed in human fibroblasts. However, no adequate in vivo 
studies  were  available  and  therefore  no  conclusion  could  be  made  on  the  genotoxicity  of 
phenylbutazone.  
In other publicly available data, it was shown that phenylbutazone was negative for chromosomal 
aberrations in in vivo bone marrow studies in rats and Chinese hamsters. However, micronuclei results 
in bone marrow cells of mice were reported to be positive as well as negative.  
Additional  new  published  data  also  show  inconsistent  findings  with  one  paper  reporting  that 
phenylbutazone was negative in bacterial mutation assays with S. typhimurium strains TA97a, TA98, 
TA100 and TA102, but caused an increase in sister chromatid exchange (SCE) in bone marrow cells 
of male mice, after intraperitoneal administration (50, 100 and 200 mg/kg body weight (b.w.)).  
In summary, the results of the tests available are inconsistent with regard to phenylbutazone’s possible 
chromosomal effects in experimental animal studies but the weight of evidence from the in vitro data 
indicates that phenylbutazone is unlikely to cause gene mutations.  
There is conflicting evidence in the human chromosomal aberration studies especially with regard to 
dose-response. 
The review of the previous evaluation confirms that on the basis of the data available on genotoxicity 
it is not possible to conclude on the genotoxic potential of phenylbutazone. 
2.1.3.  Carcinogenicity 
The 1997 CVMP summary report evaluated two studies in rats and one in mice. Following a 2-year 
exposure  to  phenylbutazone,  positive  dose-dependent  trends  were  observed  in  female  rats  for 
leukaemia, hepatic neoplasms and adrenal pheochromocytomas. In a 103-week study in rats exposed 
to phenylbutazone, small numbers of renal tubular cell adenomas and carcinomas were seen in male 
rats and tubular cell adenomas and transitional cell carcinomas of the pelvic epithelium were seen in 
females. Adrenal gland medullary hyperplasia was significantly increased in the high dose females. In 
addition,  an  increased  incidence  of  histiocytic  infiltration  of  the  lung  was  seen  in  the  high  dose 
females and a statistically decreased incidence of mammary fibroadenomas was seen in the high dose 
females with a significant negative trend. 
In a 103-week study in mice, hepatocellular adenomas or hepatocellular adenomas and carcinomas 
combined  showed  significant  positive  trends  in  male  mice,  whereas  a  significant  decrease  in 
lymphomas was seen in high dose male mice compared to controls. Severe liver toxicity was observed 
in mice (see Section 2.1.5).  
No NOELs for neoplastic or non-neoplastic effects could be identified from these studies. Phenylbutazone in horse meat  
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The CVMP concluded that phenylbutazone is probably carcinogenic to male mice and female rats as 
indicated by the results available from these studies. No further data have been published since the 
CVMP report.  
It was furthermore noted that the rat kidney tumours observed were associated with inflammation, 
papillary  necrosis  and  mineralization,  whereas  the  mouse  liver  tumours  were  associated  with 
haemorrhage, centrilobular cytomegaly and kariomegaly, fatty metamorphosis, cellular degeneration 
and  coagulative  necrosis.  Species/sex  specificity  was  also  observed.    In  both  cases  it  would  be 
plausible to assume that tumour formation occurred as a consequence of tissue damage/toxicity above 
a certain threshold. However, since genotoxicity data are inconclusive, a genotoxic mode of action 
cannot be excluded for rodent tumour formation.  
2.1.4.  Reproductive toxicity 
The 1997 CVMP summary report indicated that there were no adequate reproductive or teratology 
studies available. However, there were two studies in rats that compared the reproductive toxicity of a 
number of NSAIDs and other pharmaceuticals, including phenylbutazone. Severe maternal toxicity 
was  reported  and  there  was  evidence  of  fetotoxicity  in  offspring  of  female  rats  exposed  to 
phenylbutazone for 14 days prior to mating through weaning. Neonatal viability and survival were 
decreased in the absence of maternal toxicity as well as reductions in implantations and decreased 
foetal and litter weights.  No NOELs could be derived from the available data. 
The  original  CVMP  conclusions  on  reproductive  toxicity  remain  as  no  further  data  have  become 
available since the CVMP report. 
2.1.5.  Subchronic and chronic toxicity 
In the 1997 CVMP summary report several toxicity studies were described in mice, rats and cats. 
In a 13-week study in mice, half of the animals died.  Liver weights were significantly increased at 
300 or 600 mg phenylbutazone/kg b.w. per day. The NOEL for this study was 150 mg/kg b.w. per day. 
In a 2-year carcinogenicity study, also degeneration, haemorrhages and necrosis were observed in the 
liver  of  male  mice  even  at  the  lowest  dose  of  150  mg/kg  b.w.  per  day  at  which  there  was  no 
statistically significant increase in liver tumours.  
In a 13-week study in rats, similar mortality occurred as well as clinical effects including diarrhoea, 
and poor grooming. Body weights were found significantly lower and liver weights were significantly 
increased.  Renal  papillary  necrosis,  papillary  oedema  and  mineralisation  were  seen  at  increased 
incidences as well as testis degeneration. Lymphoid depletion of thymus, spleen and lymph nodes was 
also observed. The NOEL for this study was 25 mg/kg b.w. per day. 
Following  an  oral  exposure  of  cats  (5  animals)  to  phenylbutazone  for  21  days,  weight  loss  and 
inappetance with clinical symptoms of alopecia, dehydration, vomiting and depression were observed. 
Deaths  occurred  from  day  12,  with  one  animal  surviving  to  the  end  of  the  study  in  a  moribund 
condition. Erythrocyte count and  haemoglobin  concentration  were  decreased. Renal  damage, bone 
marrow depression and a reduction in erythroblasts were reported at post mortem, but agranulocytosis 
was  not  detected.  No  toxic  effects  were  reported  in  a  cat  that  received  fortnightly  doses  of 
2 x 12-16 mg phenylbutazone/kg b.w. for one year. 
In conclusion, kidney and liver toxicity were considered the most relevant toxic effects identified in 
rats and mice, respectively. While no NOEL could be established for hepatotoxicity from the chronic 
toxicity studies, the lowest NOEL identified for rats for nephrotoxicity in a sub-chronic study was 
25 mg/kg b.w. per day.  Phenylbutazone in horse meat  
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2.2.  Conclusions on hazard identification and characterisation 
Since the CVMP assessment in 1997, very limited new information on phenylbutazone has emerged in 
the literature.  
The conclusions on the hazard identification and characterisation can be summarised as follows: 
  The  most  critical  potential  safety  findings  related  to  toxicity  of  phenylbutazone  were  the 
idiosyncratic effects on bone marrow (blood dyscrasias including aplastic anaemia). While 
aplastic anaemia is a rare event after therapeutic use in human (≈1:30 000) it is nevertheless a 
potential  life-threatening  condition.  The  mechanism  is  unknown  and  it  is  not  possible  to 
determine a threshold for blood dyscrasias.  
  For  mutagenicity  the  results  indicate  no  genotoxic  potential  on  bacterial  systems,  and 
equivocal results in mammalian systems. Although at present the weight of evidence indicates 
that phenylbutazone is unlikely to show relevant genotoxic effects under in vivo conditions, no 
conclusive in vivo genotoxicity studies are available and hence no final conclusion can be 
drawn. 
  Phenylbutazone  is  probably  carcinogenic  to  male  mice  (liver  tumours)  and  female  rats 
(kidney/urinary tract tumours) as was concluded in the 1997 CVMP report. The hepatotoxicity 
and nephrotoxicity seen, including significant pathological effects, indicate a potential for a 
(non-geno)toxic nature of tumour induction; however, the genotoxicity data are not conclusive 
and therefore no firm conclusion can be made on the carcinogenic mode of action. No NOELs 
following chronic exposure for neoplastic or non-neoplastic effects could be identified. 
  No  adequate  data  on  reproductive  toxicity  are  available  and  therefore  no  NOELs  can  be 
derived. 
  Nephrotoxicity and hepatoxicity are considered to be the main toxic effects in rats and mice, 
respectively. The lowest NOEL of 25 mg/kg b.w. was identified for nephrotoxicity from a 
sub-chronic study in rats. 
 
3.  Exposure assessment 
3.1.  Prevalence of phenylbutazone in horse samples 
The occurrence data considered in this scientific statement were collected in the framework of the 
National  Residue  Control  Plans  (NRCP),  for  which  the  results  are  published  in  annual  reports. 
However, these reports could not be used because inherent limitations already underlined by EFSA 
(EFSA, 2010) and specific data requests had to be sent to the individual Member State.   
The NRCP results from 19 Member States collated  in the framework  of this scientific statement, 
representing a total of 2 386 samples taken from years 2005 to 2013, were used (Table B1, Appendix 
B). 
A limitation of this dataset is represented by the high heterogeneity present in the analysed matrices, 
the  sampling  strategies  and  analytical  performances.  In  particular  it  is  noted  that  the  presence  of 
phenylbutazone is monitored in different matrices including kidney, liver, serum, plasma and muscle. 
Substantial variability of the sample proportion was observed among different Member States with in 
some cases an extremely low number of samples. Finally, some differences of around a factor of 10 
were observed in the limits of quantification or CCalpha reported for the different matrices. Phenylbutazone in horse meat  
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Overall, 37 samples (1.6 %) were reported for phenylbutazone. Kidney was the matrix with the highest 
detection rate (2.8 % positive samples corresponding to 33 out of 1 160 kidney samples) and highest 
levels measured (from traces up to 1900 µg/kg, with a median at 4.0 µg/kg). Only one sample of 
muscle out of 672 (0.1 %) was reported positive, with phenylbutazone at 19.2 µg/kg.  
From these data, the prevalence of horse carcasses testing positive for phenylbutazone was calculated 
to be on average 0.13 %, weighted according to annual production across EU countries. A statistical 
analysis  performed  in  order  to  assess  the  uncertainty  around  the  prevalence  of  horse  carcasses 
containing phenylbutazone in the EU showed that, due to the low number of samples available in 
some countries, the prevalence at the EU level would be below 7.2 % with a 95 % confidence level 
(see Appendix D). The UK is among the Member States which reported the highest detection rates of 
phenylbutazone  in  horse  samples  in  the  last  years,  with  a  3.5  %  percentage  of  positive  samples 
(17/480) since the beginning of 2013 in the framework of the UK-Food Standards Agency (FSA) 
‘100 % testing of horse carcasses’. This prevalence of 3.5 % was retained as a high estimate for the 
EU prevalence. This estimate was within the uncertainty range of the statistical analysis performed. 
3.2.  Prevalence of beef-based products adulterated with horse meat 
The presence of horse meat in beef-based products was estimated considering the results from industry 
tests reported by the UK-Food Standards Agency (FSA) and the Food Safety Authority of Ireland 
(FSAI), from the UK wide survey of beef products and from the RASFF notifications. Overall, horse 
meat was found in around 1 % of the samples tested, with 2 % being considered a high bounding 
estimate. The beef-based products most frequently found positive for horse meat were pasta with meat, 
meat burgers, meat balls, beef goulash, beef stewed and frozen pieces of beef. The percentage of horse 
meat measured represented up to 100 % of the meat content in pasta with meat, 90 % of the meat 
content in burgers and meatballs, 80 % of the meat stewed, and 70 % of the meat content in the other 
beef-based products (see Appendix B for further details).  
3.3.  Likelihood of dietary exposure to phenylbutazone 
The  likelihood  of  dietary  exposure  to  phenylbutazone  was  estimated  at  the  consumer  level  by 
combining the frequency of consumption of horse meat or beef-based products potentially adulterated 
with  horse  meat  (details  on  consumption  data  reported  in  Appendix  B)  with  the  prevalence  of 
phenylbutazone in horse meat. An estimate of the number of individuals per 100 million potentially 
exposed  each  day  to  phenylbutazone  was  then  derived  at  the  population  level  by  combining  the 
likelihood of exposure at the individual level together with the estimated number of consumers of 
horse meat or beef-based products within the population.  
The estimated likelihood of dietary exposure to phenylbutazone is higher for the consumers of horse 
meat than for the consumers of beef-based products potentially adulterated with horse meat. Based on 
a horse meat consumption frequency of twice a week and a prevalence of phenylbutazone in horse 
meat  at  3.5  %,  a  consumer  would  be  exposed  to  phenylbutazone  once  every  4  months.  Using  a 
conservative scenario (beef-based products consumption frequency of four times a week, 2 % of the 
beef-based  products  containing  horse  meat,  3.5  %  (see  Section  3.1)  of  horse  meat  containing 
phenylbutazone), a consumer of beef-based products could be exposed to phenylbutazone once every 
6.8 years. 
At the population level, and across different country and age groups, this would represent from up to 
144  to  up  to  approximately  30 300  individuals  per  100  million  potentially  exposed  each  day  to 
phenylbutazone through the consumption of horse meat or horse meat products, and from up to 5 to up 
to 36 800 individuals per 100 million through the consumption of beef-based products adulterated with 
horse meat. The details on the exposure likelihood estimations are reported in Appendix B. Phenylbutazone in horse meat  
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3.4.  Levels of exposure to phenylbutazone 
Considering the  likelihood  of  exposure to phenylbutazone, only  infrequent events  of  exposure are 
foreseen  at  the  individual  level  for  both  horse  meat  consumers  and  for  consumers  of  beef-based 
products potentially adulterated with horse meat. For this reason, the estimation of chronic exposure 
levels were not considered relevant, and only the acute levels resulting from a single day of exposure 
were estimated. The acute levels of exposure were higher in children than in adolescents and in adults.  
Assuming  exposure  via horse  meat contaminated at the  highest levels  measured  in  horse samples 
(1900 µg/kg phenylbutazone measured in kidney), the average acute exposure from the consumption 
of horse meat or adulterated beef-based products was estimated to range across the population groups 
from 2.24 to 9.69 µg/kg b.w. per day for children and from 1.38 to 4.42 µg/kg b.w. per day  for 
adolescents  and  adults.  The  95
th  percentile  acute  exposure  was  estimated  to  range  across  the 
population groups from 4.50 to 15.55 µg/kg b.w. per day for children, and from 2.74 to 9.00 µg/kg 
b.w. per day in adolescents and adults. When considering horse meat containing phenylbutazone at a 
level equal to that measured in the only positive muscle sample reported (19.2 µg/kg), average acute 
exposure  levels  ranging  from  0.02  to  0.10  µg/kg  b.w.  per  day  for  the  children  and  from  0.01  to 
0.04 µg/kg b.w. per day for the adolescents and adults were  estimated. The 95
th percentage acute 
exposure levels were estimated to range from 0.05 to 0.16 µg/kg b.w. per day for the children, and 
from 0.03 to 0.09 µg/kg b.w. per day for the adolescents and adults. The details on the exposure level 
estimations are reported in Appendix B. 
4.  Risk characterisation 
The main hazards identified for residues of phenylbutazone are blood dyscrasias, genotoxicity and 
carcinogenicity. 
Blood dyscrasias 
The  occurrence  of blood  dyscrasias following therapeutic use of phenylbutazone (with therapeutic 
doses ranging from 200 to 600 mg/person per day) in humans is low (approximately 1 in 30 000). 
However it is considered that this effect might occur at lower exposure levels in sensitive humans. 
Given that a threshold level cannot be set for the idiosyncratic reactions observed in humans, a risk to 
human  health  following  exposure  to  any  amount  of  phenylbutazone,  although  low,  cannot  be 
excluded.   
In the absence  of a threshold for the  idiosyncratic  effects  of phenylbutazone,  no  quantitative risk 
characterisation can be carried out. However, the likelihood that cases of blood dyscrasias could arise 
from dietary exposure to phenylbutazone as a result of the recent fraudulent practices was estimated 
by considering the overall likelihood that susceptible subjects were exposed to the substance (either 
via  direct  consumption  or  contaminated  horse  meat  or  the  consumption  of  beef-based  products 
containing contaminated horse meat). Considering the different scenarios, the daily probability for an 
individual both to be a subject susceptible to develop anaemia and to be exposed to phenylbutazone 
was estimated to range from 2 in a trillion up to 1 in 100 million. 
Genotoxicity/carcinogenicity  
Data on genotoxicity are equivocal, and it is not possible to conclude that a genotoxic mode of action 
is responsible for the carcinogenicity observed in laboratory animals.  However it is noted from studies 
in rodents that the tumours are most associated with organs that also show adverse effects at the lowest 
doses tested, indicating that the carcinogenicity might be linked to organ toxicity rather than direct 
genotoxicity. The doses at which organ toxicity and carcinogenicity were observed are more than three 
orders  of  magnitude  higher  than  those  that  could  be  expected  from  potential  exposure  to 
phenylbutazone from horse meat.  In addition those effects were observed following chronic exposure 
which is unlikely to be the case in relation to the frequency of exposure events to humans from the Phenylbutazone in horse meat  
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consumption  of  horse  meat containing phenylbutazone. Therefore  it  is considered that the risk  of 
carcinogenicity to humans from this exposure is of very low concern. 
5.  Uncertainty analysis 
An evaluation of the inherent uncertainties in the assessment of exposure to phenylbutazone has been 
performed following the guidance of the Opinion of the Scientific Committee related to Uncertainties 
in  Dietary  Exposure  Assessment  (EFSA,  2006).  In  addition,  the  report  on  ‘Characterizing  and 
Communicating Uncertainty in Exposure Assessment’ has been considered (WHO-IPCS, 2008).  
The summary of uncertainties is reported in Table 1. A full discussion of the uncertainties identified is 
given in Appendix D. 
The uncertainties are mainly related to the limited information available to estimate the prevalence and 
levels of phenylbutazone in horse meat, the prevalence of fraudulent practices which entails replacing 
beef meat by horse meat in beef-based products, and the consumption habits of horse meat throughout 
Europe. However, assumptions were made in this regard in order to be conservative.  
Table 1:   Summary of qualitative evaluation of the impact of uncertainties on the risk assessment of 
the exposure of phenylbutazone in horse meat. 
Sources of uncertainty  Direction
(a)  
Occurrence data originating from target sampling, which may not be representative  + 
Low number of samples available in some countries in regards to their annual production 
level of horse carcasses 
+/- 
Occurrence and maximum levels of phenylbutazone measured in parts of the animals not 
intended for consumption were taken as representative of the levels in horse meat. 
+ 
Uncertainty related to the assumption that 90 % of processed beef meat was replaced by 
horse meat in meat burgers/meatballs, 80 % in beef stewed and 30 % in minced/grounded 
beef 
+  
Uncertainty related to the assumption that 0.1, 1 and 2 % of the beef-based products would 
contains horse meat 
+ 
Uncertainty related to the assumption that horse offal could be illicitly used in beef-based 
products 
+ 
Insufficient data on the presence of oxyphenbutazone in horse meat   - 
Limited  reliability  of  the  data  on  horse  meat  consumption  available  in  the  EFSA 
Comprehensive European Food Consumption Database. 
+/- 
Consumption surveys not detailing the kind of meat used in meat products and reporting data 
disaggregated at the ingredient level for processed beef meat products   
+/- 
A  single  estimate  of  prevalence  at  European  level  without  considering  the  possible 
variability throughout Europe 
+/- 
Incidence of aplastic anaemia observed in the therapeutic use of the substance considered to 
calculate the probability of potential cases of blood dyscrasias in relation to exposure from 
horse meat containing phenylbutazone 
+ 
(a):  + = uncertainty with potential to cause over-estimation of exposure/risk; - = uncertainty with potential to cause under-
estimation of exposure/risk. 
 
 
It is important to acknowledge that the current assessment is restricted to horse meat and to potentially 
adulterated beef-based products. The presence of residues of phenylbutazone has been rarely reported 
in bovine animals (EFSA, 2011a, 2012, 2013), which has not been specifically taken into account in 
the  estimation  of  the  likelihood  of  exposure.  Moreover,  due  to  the  lack  of  occurrence  data  on 
oxyphenbutazone and on its concurrent presence with phenylbutazone, this metabolite has not been 
taken into consideration in the exposure assessment. 
It is considered that the impact of the uncertainties on the risk assessment regarding human exposure 
to residues of phenylbutazone in horse meat is considerable, however, it can be concluded that the risk 
assessment  of  human  exposure  considered  in  the  statement  is  likely  to  overestimate  the  risk.Phenylbutazone in horse meat  
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CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
Phenylbutazone is not authorised for use in food-producing animals as maximum residue limits are not 
established for the substance.  In 1997, the Committee for Medicinal Products for  Veterinary  Use 
(CVMP)  assessed  the  consumer  safety  of  phenylbutazone  and  concluded  that  no  acceptable  daily 
intake (ADI) could be established hence no maximum residue limits (MRL) could be recommended. 
Controls in Member States have however revealed the presence of residues of phenylbutazone in horse 
meat which indicate an illegal use of carcasses of horses treated with this pharmacological substance. 
On 28 February 2013, the European Commission asked the European Food Safety Authority (EFSA) 
and the European Medicines  Agency (EMA) for a joint statement regarding a risk assessment on 
residues of phenylbutazone in horse meat, from direct consumption of horse meat as well as from 
other products adulterated with such food. 
It must be noted that the risk assessment has been performed on the basis of limited data in terms of 
toxicity of phenylbutazone as well as in terms of actual occurrence data reported in horse meat across 
the EU, which had been sampled in the previous years only occasionally, using diverse sampling and 
detection methods.  In view of the assumptions made to address most of the existing uncertainties, it 
was concluded that the current risk assessment is likely to overestimate the risks.  
The European Food Safety Authority and the European Medicines Agency conclude that: 
  The safety assessment performed by the CVMP regarding phenylbutazone in 1997 has been 
confirmed in the absence of any relevant new data. Therefore EMA and EFSA confirmed that 
it is not possible to establish safe levels for phenylbutazone in food. In relation to the risk to 
the  consumer,  the  main  concerns  remain  idiosyncratic  blood  dyscrasias  and  the 
genotoxic/carcinogenic potential. No thresholds could be identified. 
  The occurrence of blood dyscrasias following therapeutic use of phenylbutazone in humans is 
low (approximately 1 in 30 000).  In the absence of dose response data it is considered that this 
effect might occur at lower exposure levels in sensitive humans.  
  Data on genotoxicity are equivocal and a genotoxic mode of action for carcinogenicity cannot 
be excluded but it is considered most likely that the carcinogenicity observed in laboratory 
animals might be linked to organ toxicity.   
  The results from the National Residue Control Plans (NRCP) from 19 Member States collated 
in the framework of this scientific statement were used to estimate the prevalence of horse 
meat containing phenylbutazone and the level to which consumers may have been exposed. 
  Thirty seven samples out of 2 386 samples taken from years 2005 to 2013 were found positive 
for phenylbutazone. Kidney was the matrix with the highest detection rate (2.8 % (33/1 160) 
and  highest  levels  measured  (up  to  1900  µg/kg).  Only  one  sample  of  muscle  out  of  672 
(0.1 %) was found positive, with phenylbutazone at 19.2 µg/kg. 
  The likelihood of dietary exposure to phenylbutazone was estimated at the consumer level by 
combining the frequency of consumption of horse meat or beef-based products potentially 
adulterated with horse meat with the prevalence of phenylbutazone in horse meat.  
  Based  on  a  horse  meat  consumption  frequency  of  twice  a  week  and  a  prevalence  of 
phenylbutazone in horse meat of 3.5 %, which is considered as a conservative scenario, the 
probability  of  exposure  of  a  consumer  to  phenylbutazone  would  be  once  every Phenylbutazone in horse meat  
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4 months. Lower probabilities of exposure were estimated for consumption, from two to four 
times a week, of beef-based products potentially adulterated with horse meat. 
  At the population level and across different countries and age groups, up to 144 individuals to 
up to approximately 30 300 individuals per 100 million have been potentially exposed each 
day to phenylbutazone through the consumption of horse meat or horse meat products, and up 
to  5  to  up  to  36 800  individuals  per  100  million  have  been  potentially  exposed  each  day 
through the consumption of beef-based products adulterated with horse meat.  
  Considering the infrequent events of exposure, only the acute levels resulting from a single 
day  of  exposure  were  estimated.  The  estimated  acute  levels  of  exposure  were  higher  in 
children than in adolescents and in adults.  
  Assuming horse meat contaminated at the highest levels measured in horse samples (measured 
in a kidney sample), an average acute exposure up to 9.69 µg/kg body weight (b.w.) per day, 
and a 95
th percentile acute exposure up to 15.55 µg/kg b.w. per day were estimated from the 
consumption  of  horse  meat  or  adulterated  beef-based  products.  Lower  exposure  can  be 
expected due to the lower concentration likely to be found in muscle in comparison to kidney.  
  There is uncertainty about the risk to potential exposure to oxyphenbutazone which was not 
taken  into  account  in  the  current  assessment.  Oxyphenbutazone  was  also  detected  in  one 
muscle  sample  at  a  concentration  higher  than  phenylbutazone  in  the  same  sample. 
Oxyphenbutazone is a major metabolite in horses with a slower elimination following daily 
administration to horses which is often the case in veterinary practice.   
  In the absence of a threshold of toxicity for the idiosyncratic effects of phenylbutazone, no 
quantitative risk characterisation could be carried out. However, the likelihood that cases of 
blood dyscrasias could arise from dietary exposure to phenylbutazone as a result of the recent 
fraudulent practices was estimated by considering the overall likelihood that sensitive subjects 
were exposed to the substance (either via direct consumption or contaminated horse meat or 
the  consumption  of  beef  products  containing  contaminated  horse  meat).  Considering  the 
different scenarios, on one given day the probability for an individual both to be a subject 
susceptible to develop aplastic anaemia and to be exposed to phenylbutazone was estimated to 
range approximately from 2 in a trillion to up to 1 in 100 million. 
  The doses at which organ toxicity was observed in experimental studies in laboratory animals 
are  more  than  three  orders  of  magnitude  higher  than  those  that  could  be  expected  from 
potential exposure to phenylbutazone from horse meat consumed as such or present in beef-
based products. In addition those effects were observed following chronic exposure which is 
unlikely to be the case in relation to the frequency of exposure events from the consumption of 
horse  meat  containing  phenylbutazone.  Therefore  it  is  considered  that  the  risk  of 
carcinogenicity to humans from this exposure is of very low concern. 
RECOMMENDATIONS 
The findings of residues of phenylbutazone in horse meat result from horse carcasses entering the food 
chain  illegally.  With  the  aim  of  improving  controls  and  minimising  the  risk  the  following 
recommendations are made: 
  A reliable identification system to improve traceability of horses, including strengthening the 
‘horse passport’ system, with appropriate and effective enforcement.    
  As the sampling intensity and methods for horses varies substantially between Member States, 
harmonised control measures in terms of sampling and performance of analytical methods in 
relation to phenylbutazone should be considered. Phenylbutazone in horse meat  
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  Improvement  of  data  reporting  methodology  concerning  monitoring  of  veterinary  drug 
residues  and  other  substances  by  Member  States  under  Council  Directive  96/23/EC,  as 
recommended by EFSA (2012). 
  Monitoring  of the  main  metabolite  oxyphenbutazone considering its slower  elimination  in 
horses and the likely similar pharmacological effects and toxicity of oxyphenbutazone and 
phenylbutazone. 
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APPENDICES 
Appendix A.   Summary report CVMP (1997) 
EMEA/MRL/297/97-FINAL 
October 1997 
 
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 
PHENYLBUTAZONE 
SUMMARY REPORT 
 
1.  Phenylbutazone  (4-butyl,1,2-diphenylpyrazolidone-3,5-dione)  is  a  synthetic  pyrazolone 
derivative  with  anti-inflammatory,  antipyretic  and  analgesic  properties.  In  veterinary  medicine 
phenylbutazone is used in mono-preparations by oral or parenteral administration, or in conjunction 
with  ramifenazone  and  is  administered  by  intramuscular  or  slow  intravenous  injection. 
Phenylbutazone  preparations  are  indicated  for  use  in  horses  as  an  adjunct  to  therapy  in  many 
inflammatory conditions of the musculoskeletal and locomotor systems. Recommended dosages are 
between 2.2-9 mg/kg bw/day for a maximum of 12 days. A 2:1 combination product of ramifenazone 
and phenylbutazone is available for similar indications in horses, cattle and pigs. The recommended 
dose is 7 mg/kg bw for horses and cattle parenterally, 14 mg/kg bw for calves and pigs parenterally, or 
20 g/horse or 8 g/pig rectally.  
2.  Phenylbutazone is a non-steroidal anti-inflammatory drug (NSAID), classified as an enolic 
acid.  In  common  with  other  non-steroidal  anti-inflammatory  drugs  phenylbutazone  exerts  its 
pharmacological  and  toxicological  effects  through  inhibition  of  the  prostaglandin  endoperoxide 
synthetase system. The ED50 for the inhibition of prostaglandin synthesis in a carrageenin exudate 
study in the rat was 3 x 2.8 mg phenylbutazone/kg bw/day. Phenylbutazone has variable antipyretic 
activity in different species. In the rat the effective dose is approximately 140 mg/kg. In the rabbit, 
pyrexia was reduced by 70-80%, the effect lasting for at least 3 hours after intravenous doses of 40 or 
70 mg/kg phenylbutazone. Oral administration of doses of phenylbutazone of 20-200 mg/kg to mice, 
increased reaction time to thermal irritation and hot plate exposure by around 20-30% and 30-40%, 
respectively in a dose-dependent manner. Intraperitoneal administration of phenylbutazone in mice 
inhibits  acetic  acid-induced  abdominal  pain.  The  ED50  was  reported  as  20  mg/kg.  In  the  cat, 
intravenous doses of phenylbutazone have a normotensive or hypertensive effect on blood pressure; 
phenylbutazone has no sedating or spasmolytic effects. Some non-steroidal anti-inflammatory drugs 
such as phenylbutazone and aspirin irreversibly inhibit platelet cyclo-oxygenase, blocking formation 
of thromoboxane  A2, thus  inhibiting platelet aggregation, thrombosis and  haemostasis. It was  not 
possible to determine a pharmacological NOEL from the data available. 
3.  Radiolabel  studies  in  the  rat  indicated  rapid  and  almost  complete  absorption  of 
phenylbutazone following oral exposure. In male rats dosed with 15 mg/kg bw, over 50% of the dose 
was excreted in the urine within 24 hours. After 48 hours approximately 95% of the total dose was 
recovered, 60% in urine and 35% in faeces. In female rats given doses of 10 mg/kg bw by gavage, 
about 88% of the dose was recovered in the urine and faeces within 96 hours. Phenylbutazone binds 
strongly to plasma proteins with around 1/4-1/3 of the dose localised in the plasma and binding in 
plasma  of  over  90%  being  reported  in  various  species.  In  rats  and  dogs  the  highest  tissue 
concentrations are seen in the kidney and liver. Phenylbutazone in horse meat  
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4.  A number of metabolites have been identified, including oxyphenbutazone,  
γ-hydroxyphenyl-butazone, p-γ-hydroxyphenylbutazone, and C-glucuronides of phenylbutazone and 
γ-hydroxy-phenylbutazone. Metabolism to oxyphenbutazone and γ-hydroxyphenylbutazones appears 
to  represent  the  major  metabolic  pathway  in  most  species.  Metabolism  and  excretion  of 
phenylbutazone were measured in the rat following administration of a radiolabelled dose of 15 mg/kg 
bw  by  oral  gavage.  Comparison  of  faecal  and  biliary  excretion  suggested  that  entero-hepatic 
recirculation was insignificant. The elimination half-life in most laboratory animals, pigs and horses is 
around 5-8 hours, except for goats (15 hours) and cattle (37-66 hours). 
5.  In humans rapid and almost complete absorption from oral administration (71-89% excretion) 
is reported. Intramuscular absorption is relatively slow. Following administration of 800 mg doses to 
humans by oral or intramuscular routes absorption was greater by the oral route, plasma levels peaking 
at two hours. Intramuscular absorption peaked between 6-10 hours, by 24 hours plasma levels were 
similar for both routes. It is reported that phenylbutazone is extensively metabolised in humans with 
about only 1% being excreted unchanged in the urine. About 50% of the excreted dose is composed of 
C-4 glucuronides of phenylbutazone (40%) and γ-hydroxyphenylbutazone (12%) and only about 10% 
other known metabolites. In humans highest tissue levels were reported in post-mortem samples from 
adrenals, kidney and lung. Excretion in humans is slow, 21 days after application of a single 400 mg 
labelled dose only 88% (61% in urine and 26% in faeces) of the radioactivity had been recovered. The 
elimination half-life in humans is 66-88 hours. The major differences in metabolism between humans 
and  laboratory species appear to be that in  humans both C-glucuronidation and  hydroxylation are 
involved, whereas in the rat and dog metabolism is predominantly through hydroxylation. It is claimed 
that this may account for the difference in elimination rates. In humans half-life is dose-dependent, 
increasing with dose over the therapeutic dose-range (1.7-3 mg/kg bw). 
6.  The  study  of  phenylbutazone  half-life  in  monozygotic  and  dizygotic  twins  showed  little 
difference  in  half-life  between  monozygotic  twins,  but  significantly  greater  differences  between 
dizygotic twins. This indicates that a genetic element may be responsible for the wide variation in 
phenylbutazone metabolism in humans. Pretreatment with oxyphenbutazone increases the half-life in 
the rat and decreases plasma clearance. Phenobarbitone decreases the half-life of phenylbutazone. This 
can  result  in  increased  plasma  levels  of  unbound  pharmacologically  active  parent  compound. 
Phenylbutazone is known to interact with the pharmacokinetics of many other compounds, including 
hydrocortisone,  tolbutamide  and  aminopyrine,  cholestyramine,  anticoagulants,  sulphonylureas, 
phenytoin, methotrexate and lithium, leading to increased toxicity.  
7.  Acute oral LD50 values are reported for the mouse (442-700 mg/kg bw), rat (360-1000 mg/kg 
bw) and guinea pig (250-1220 mg/kg bw). Necrotic ulcers and gastric haemorrhage were reported in 
rats dosed orally with 300 mg/kg phenylbutazone and sacrificed between 4-24 hours after dosing. 
Significant diurnal effects were reported in male rats; oral LD50 value were 710 mg/kg bw a.m., and 
525 mg/kg bw p.m. In a single dose study comparing the ulcerogenic effects of 10 non-steroidal anti-
inflammatory drugs, phenylbutazone showed one of the lowest ulcerogenic indices. 
8.  In 19-day repeated dose studies groups of 5 male and 5 female mice received daily oral doses 
of 0, 40, 80, 150, 300 or 600 mg/kg bw by gavage. No effects on body weights or clinical signs were 
reported. In rats (5 males and 5 females/group) receiving oral daily doses of 0, 40, 80, 150, 300 or 
600 mg/kg bw for 19 days, 3 males and 4 high-dose females and 2 females at 300 mg/kg died due to 
phenylbutazone  treatment,  all  deaths  occurring  on  days  2-20  of  treatment.  Body  weights  were 
significantly depressed at doses greater than 300 mg/kg bw. NOELs could not be determined from 
these studies as no data on haematology, clinical chemistry or histopathology were reported. 
9.  In  a  13-week  study,  groups  of  10  male  and  10  female  mice  received  daily  oral  doses 
(5 days/week) of 0, 40, 80, 150, 300 or 600 mg phenylbutazone/kg bw. Five male and 4 female high 
dose animals died before the end of the study, but no effects on bodyweights or clinical signs were 
observed. Liver weights were significantly increased in both sexes at 300 and 600 mg/kg bw. No Phenylbutazone in horse meat  
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treatment-related pathology was observed. The NOEL was 150 mg/kg bw. Groups of 10 male and 
10 female rats received daily oral doses (5 days/week) of 0, 25, 50, 100, 200 or 300 mg/kg bw. Seven 
male and 8 female high dose animals, and male and 2 females at 200 mg/kg bw died between weeks 
1-9 of the study. Clinical effects reported at 200 and 300 mg/kg bw included diarrhoea, poor grooming 
and chromodachryorrhea. Bodyweights were significantly lower in the 200 and 300 mg/kg bw groups 
and  liver  weights  were  significantly  increased.  Renal  papillary  necrosis,  papillary  oedema  and 
mineralisation were seen at increased incidences at doses greater than 100 mg/kg bw in males and 
greater than 50 mg/kg bw in females. Testicular degeneration was seen in 4/6 males at 300 mg/kg, 
2/10 males at 200 mg/kg and 1/10 males at 100 mg/kg. Lymphoid depletion of thymus, spleen and 
lymph nodes was seen in 6/7 males and 6/8 females at 300 mg/kg and 1 male and 1 female at 200 
mg/kg,  this  lesion  was  only  seen  in  animals  dying  before  the  end  of  the  study.  The  NOEL  was 
25 mg/kg bw. 
10.  In a chronic study, single dogs were given 10, 100 or 200-250 mg phenylbutazone/kg bw/day 
orally for 90 days. No adverse effects were seen in the animals receiving 10 or 100 mg/kg. The high 
dose animal developed vomiting, bloody diarrhoea and soft stools after 2 days. Soft stools were seen 
in  the  second  week,  inappetance  and  anorexia  developed  at  week  nine  until  death  in  week  12. 
Haematology  was  normal  in  the  lower  dose  animals.  The  high  dose  animal  was  mildly  anaemic 
throughout. No treatment related lesions were found grossly or at microscopic examination of liver 
spleen kidney or bone marrow. This study was not conducted to GLP standards and a NOEL could not 
be  determined  due to the small  number  of animals  used and the  limited  laboratory investigations 
conducted. 
11.  Cats were exposed to oral daily doses of 44 mg phenylbutazone/kg bw for 21 days. Weight 
loss  and  inappetance  occurred  with  clinical  symptoms  of  alopecia,  dehydration,  vomiting  and 
depression. Deaths occurred from day 12, one animal survived to the end of the study in a moribund 
condition. Erythrocyte count and  haemoglobin  concentration  were  decreased. Renal  damage, bone 
marrow depression and a reduction in erythroblasts were reported at post mortem, but agranulocytosis 
was not detected. No toxic effects were reported in a cat that received fortnightly doses of 2 x 12-16 
mg phenylbutazone/kg bw for one year. 
12.  Adverse  clinical  signs  of  intolerance  reported  in  horses  include  depression,  listlessness, 
inappetance, gingival and lingual ulceration, diarrhoea, anorexia, abdominal and preputial oedema, 
recumbency, shock and death. Necropsy findings include ulceration of the oral mucosa, stomach and 
(unlike  other species) large bowel, with peritonitis. Renal papillary necrosis  has been  observed  in 
horses but it is suggested that this may not be a direct effect of phenylbutazone, but due to dehydration 
or  coadministration  of  other  nephrotoxic  drugs,  however,  use  is  contraindicated  in  these 
circumstances. Hepatotoxicity has been reported in horses given oral doses of 8.8 mg/kg bw for four 
days or 7.5 mg/kg bw for eight days.    
The therapeutic window is reported to be quite narrow and adverse effects have been reported at doses 
close recommended dose rates (single doses of 8-12 mg/kg bw for more than four days or twice daily 
doses of 4.4 mg/kg bw for four days, then 2.2 mg/kg bw for seven days).  
 13.  No adequate reproductive  or teratology studies  were available. Two studies compared the 
reproductive  toxicology  of  a  number  of  NSAIDs  and  other  pharmaceuticals,  including 
phenylbutazone. There was evidence of foetotoxicity in offspring of female rats exposed to a dietary 
dose of 42 mg phenylbutazone/kg bw/day for 14 days prior to mating through to weaning. Severe 
maternal toxicity was also reported. Neonatal viability and survival were decreased, in the absence of 
maternal toxicity, in offspring of female rats exposed to diets containing 44 mg/kg bw/day from day 
15 of gestation through weaning. Doses of 50, 100 or 200 mg phenylbutazone/kg bw by oral gavage to 
pregnant rats from days 6 to 15 of gestation, resulted in reductions in implantations and decreased 
foetal and litter weights. Investigations of teratogenicity in the rat and rabbit were inconclusive. No 
NOELs could be derived from these studies.  Phenylbutazone in horse meat  
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14.  An in vitro test for gene mutation using S. typhimurium strains TA98, TA100, TA1535 and 
TA1537 and doses of phenylbutazone of 33-10000 µg/plate, with and without metabolic activation (rat 
and hamster S9) was negative. Doses greater than or equal to 3333 µg phenylbutazone/plate were 
toxic to strain TA100 in the absence of metabolic activation.  
An in vitro study for gene mutation in mammalian cells using the mouse L5178Y/TK lymphoma assay 
produced significant positive responses at doses greater than or equal to 500 µg/ml without metabolic 
activation, and greater than or equal to 400 µg/ml with metabolic activation. Lethality was reported at 
doses of 600 and 800 µg/ml with and without metabolic activation. Negative findings were reported in 
further Ames Salmonella assays, B. subtilis rec-/rec+ assays and mutagenicity studies in silkworms.  
15.  In  vitro  assays  for  chromosomal  aberrations  and  sister  chromatid  exchanges  (SCE)  were 
conducted using Chinese hamster ovary (CHO) cells. No increases in SCEs were found either with or 
without metabolic activation. No increase in chromosome aberrations were seen without metabolic 
activation,  significantly  increased  incidence  of  aberrations  were  seen  with  metabolic  activation  at 
1600 and 5000 µg/ml, but not 500 µg/ml. Positive results for chromosomal aberrations have also been 
reported in cultured hamster lung fibroblasts (without activation), but negative results were obtained 
for chromosomal aberrations or SCEs in human fibroblasts. An in vitro study exposing human blood 
cells to phenylbutazone at levels of 100 mg % (cf steady-state plasma concentration at 300 mg/day of 
60-130 mg %) for 16 or 40 hours, found no evidence of chromosomal or chromatid damage. 
16.  Chromosomal  changes  were  seen  in  lymphocytes  of  humans  exposed  to  prolonged 
administration of phenylbutazone. The frequency of cells with chromosomal damage was significantly 
higher in patients taking daily doses of phenylbutazone of 100-500 mg (2%) than controls (0.48%), as 
was  the  frequency  of  dicentric  chromosomes  (0.45%  cf  0.06%).  There  was  no  evidence  of  any 
relationship between frequency of damaged cells and sex, age, duration of treatment or accumulated 
dose. 
17.  Patients presenting at clinic with indications for phenylbutazone therapy were tested before 
and during treatment. Only 3/9 patients had cells with chromosome damage (3/900 cells examined), 
prior to treatment. During treatment, chromosomal damage was found in 8/9 nine (62/3,000 cells). 
Damage was found as early as two weeks from starting treatment and all eight within 16 weeks. It was 
not possible to reach a conclusion on the mutagenicity of phenylbutazone due to the lack of adequate 
in vivo studies.  
18.  The carcinogenic potential of phenylbutazone was evaluated by the International Agency for 
Research on Cancer in 1987. The data available at that time was limited and considered insufficient to 
reach a conclusion. Since that time three studies have become available, including two GLP studies in 
rats and mice conducted for the US National Toxicology Program. 
 19.  Inbred DONRYU rats were fed diet containing 0, 1250 or 2500 mg/kg feed phenylbutazone 
for 2 years. In females dose-dependent positive trends were seen for leukaemia, hepatic neoplasms and 
adrenal pheochromocytomas. Tumour-promoting effects of phenylbutazone were also investigated in 
rats.  After  initiation  with  N-ethyl-N-nitrosourea  (ENU)  or  N-propyl-N-nitrosourea  (PNU),  animals 
received either basal diet or diet containing 2500 mg/kg feed phenylbutazone for 2 years. Rats exposed 
to  N-ethyl-N-nitrosourea  or  N-propyl-N-nitrosourea  showed  increased  incidences  of  ovarian 
neoplasms,  leukaemia,  gliomas,  intestinal  neoplasms  and  cortical  neoplasms,  incidences  of  these 
tumours  were  not  increased  by  phenylbutazone  exposure.  However  a  slight  promoting  effect  was 
noted for renal and thyroid tumours.  
20.  B6C3F1  mice  were  given  daily  oral  doses  of  phenylbutazone  (0,  150,  300  mg/kg  bw), 
5 days/week  for  103  weeks.  No  treatment-related  clinical  signs  were  reported  and  survival  was 
unaffected. Mean bodyweights were slightly decreased in the high dose. Hepatocellular adenomas or 
hepatocellular adenomas and carcinomas combined showed significant positive trends in males and 
were significantly greater at the high dose, hepatocellular neoplasms were not increased in females. 
Non-neoplastic  hepatocellular  lesions  also  showed  significant  (and  in  some  cases,  dose-related) Phenylbutazone in horse meat  
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increases.  A  significant  decrease  in  lymphomas  was  seen  in  high  dose  male  mice  compared  to 
controls. No NOEL for neoplastic or non-neoplastic effects can be derived from this study. 
21.  F344/N  rats  were  given  daily  oral  doses  of  phenylbutazone  (0,  50,  100  mg/kg  bw), 
5 days/week for 103 weeks. Survival of male low dose animals was statistically significantly lower 
than controls, survival of high dose females was slightly decreased. Bodyweights of the high dose 
were  lower  than  controls.  No  adverse  clinical  effects  were  reported.  Incidence  and  severity  of 
nephropathy and renal lesions  were significantly greater in both dose  groups and both sexes than 
controls. Small numbers of renal tubular cell adenomas and carcinomas were seen in male rats and 
tubular cell adenomas and rare transitional  cell carcinomas  of the pelvic  epithelium  were seen  in 
females. Adrenal gland medullary hyperplasia was significantly increased in the high dose females. 
Lesions of the forestomach were significantly increased in the treated males and high dose females.  
An increased incidence of histiocytic infiltration of the lung was seen in the high dose females and a 
statistically decreased incidence of mammary fibroadenomas was seen in the high dose females with a 
significant negative trend. No NOEL for neoplastic or non-neoplastic effects can be derived from this 
study. 
22.  These studies indicate that phenylbutazone is probably carcinogenic to male mice and female 
rats. There is some limited evidence that phenylbutazone can also act as a tumour promotor.  
23.  No experimental studies have been performed in animals to investigate potential immunotoxic 
effects of phenylbutazone. The data on adverse effects in humans indicates (idiosyncratic) reactions to 
the compound that have occasionally been fatal. As no mechanism has been established for the blood 
dyscrasias in humans and neutropenia was seen in some animal species, further investigation of the 
immunotoxic capability of phenylbutazone would be desirable. 
Adverse reactions are commonly reported with clinical use of phenylbutazone in humans. Between 
10-45% of patients report some type of side-effect, which cover a broad spectrum of conditions. The 
most  serious  adverse  effects  from  phenylbutazone  treatment  in  humans  are  agranulocytosis  and 
aplastic  anaemia.  Leucopenia,  pancytopenia,  haemolytic  anaemia  and  thrombocytopenia  may  also 
occur. Mortality from fatal bone marrow depression due to phenylbutazone and oxyphenbutazone is 
estimated at 2.2 and 3.8 per 100000, respectively, compared to a figure of around 2.5-5 per 100000 for 
chloramphenicol. In the UK phenylbutazone is currently only indicated for hospital use for cases of 
ankylosing spondylitis when other therapy has failed. 
 24.  Inhibition of DNA synthesis in cultured human lymphocytes in vitro by short term exposure to 
therapeutic concentrations of phenylbutazone are reported. Inhibition occurred even at the lowest dose 
tested (32 µM). In the presence of serum, phenylbutazone only caused appreciable inhibition in one 
case (dose not specified). Inhibition of DNA synthesis in cultured human bone marrow cells aspirated 
from lung cancer patients has been investigated. In bone marrow cells from two patients (both male), 
phenylbutazone caused a dose-dependent decrease in uptake of 
3H-TdR that was negated by serum, in 
the third (female), a much greater inhibition occurred and there was still inhibition in the presence of 
serum at levels of phenylbutazone (30-600 µM) well within the therapeutic range. Significant but 
slight decreases in cell viability were seen with increasing doses but at only 6% in the highest doses 
were not considered to be responsible for the effect on DNA synthesis. It was also noted that inhibition 
was brought about by only one hour's exposure and the magnitude of inhibition in the absence of 
serum  is  comparable  to  that  of  cytotoxic  drugs  used  in  treatment  of  leukaemias,  e.g.  cytosine 
arabinoside and hydroxyurea. In vitro studies to investigate effects of phenylbutazone on growth of 
bone  marrow  cells  have  been  performed  using  haematologically  normal  human  granulocyte  and 
monocyte cultures. Dose-dependent inhibition of colony formation was reported. Phenylbutazone had 
an ED50 around 180 µM. In vivo, peak plasma concentrations of phenylbutazone during treatment are 
in the region of 200-500 µM. Lymphocytes from fresh peripheral blood of nine healthy subjects were 
transformed  to  proliferating  blastic  forms  and  incubated  in  medium  containing  phenylbutazone  at 
concentrations from 30-500 µM with 
3H-TdR for one hour, both with and without the presence of 20% 
serum. Phenylbutazone caused inhibition of DNA synthesis as measured by 
3H-TdR incorporation. 
Cell  counts and trypan blue  exclusion tests  indicate  these  effects  were not  caused by  lethal toxic Phenylbutazone in horse meat  
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effects.  The  inhibitory  action  of  phenylbutazone,  on  in  vitro  growth  of  human  granulocyte  and 
monocyte colonies has also been investigated. Phenylbutazone was directly toxic to progenitor cells at 
concentrations around 250 µM. An ED50 value (concentration producing 50% inhibition of colony 
formation) was obtained of about 180 µM. 
25.  It  is  therefore  concluded  that  a  mechanism  for  phenylbutazone-induced  myelotoxicity  in 
humans has not yet been demonstrated. The clinical profile of phenylbutazone-induced dyscrasias is 
complicated. The in vitro investigations using haemopoietic progenitor cells indicate dose-dependent 
effects on DNA synthesis and chromosomal damage. However, it is difficult to relate the findings of 
these  studies  to  each  other,  or  to  the  events  in  phenylbutazone  treated  patients.  Phenylbutazone-
induced aplastic anaemia may show an insidious development after prolonged treatment, it may occur 
months  after  treatment  has  ceased,  or  occasionally  develop  acutely  often  on  rechallenge. 
Agranulocytosis on the other hand appears more closely related to drug exposure and in many cases 
occurs within days of starting treatment. No animal model exists for these myelotoxic effects. 
26.  No data are provided on either the effects of phenylbutazone on human gut flora or micro-
organisms used in food processing. Such data are not considered necessary for this class of substance.  
27.  Oxyphenbutazone and γ-hydroxyphenylbutazone are the principal metabolites and both are 
reported to exhibit anti-inflammatory activity. The available data on oxyphenbutazone was limited to 
reports of pharmacological studies, acute toxicity data and effects on the haemopoietic system. It is 
unclear  whether  phenylbutazone  or  oxyphenbutazone  is  the  more  potent  substance  in  terms  of 
pharmacological effects and toxicity to laboratory animals. However the data on myelotoxic effects 
suggest that oxyphenbutazone is more toxic than the parent compound. 
 28.  It was concluded that no ADI could be established for the following reasons: 
  The most critical known toxic effects of phenylbutazone are blood dyscrasias in humans. It is 
not possible to determine a NOEL for this effect. Phenylbutazone has been used for a range of 
indications in the past and blood dyscrasias have been reported over the range of therapeutic 
doses. The myelotoxic effects of phenylbutazone and its metabolites are analogous with the 
effects of chloramphenicol and cytotoxic drugs;  
  Phenylbutazone is nephrotoxic in the rat and hepatotoxic in the mouse. There is evidence of 
carcinogenicity in one or both sexes in both species. NOELs or minimum effect levels in these 
studies cannot be derived from these studies;  
  No adequate data on reproductive toxicity are available; 
  In vitro studies have shown evidence of mutagenic potential and examination of lymphocytes 
from  human  patients  shows  significant  increases  in  chromosomal  damage.  No  adequate 
studies to investigate the mutagenic activity of phenylbutazone in vivo have been conducted. 
29.  No radiometric studies  were presented  in the target  species,  hence no  justification for the 
choice of a  marker residue  was given and  no information  concerning the ratio  of  marker to total 
residues for any of the target species was provided. 
30.  In pigs, intravenous doses of 20 and 40 mg phenylbutazone/kg bw gave phenylbutazone Vd 
values of 0.14 and 0.22 l/kg respectively. In the same plasma samples the Vd values of the metabolite 
oxyphenbutazone  were  0.19  and  0.41  l/kg  respectively.  Elimination  data  were  also  presented  for 
commercial phenylbutazone preparations in pigs (intramuscular 7 mg/kg bw; t1/2 = 12.5 hours). The 
metabolites in 24 hour urine samples from pigs dosed intramuscularly could be ranked on the basis of 
concentration  as  follows:  oxyphenbutazone  greater  than  γ-hydroxy-phenylbutazone  greater  than 
pγ-dihydroxyphenylbutazone and greater than phenylbutazone. Phenylbutazone in horse meat  
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31.  When  ponies  were  dosed  orally  or  intravenously  with  4.4  mg  phenylbutazone/kg  bw 
(commercial formulation) the changes in plasma phenylbutazone concentrations with time fitted a two 
compartment open model. The plasma concentrations of phenylbutazone following oral administration 
indicated a mean bioavailability of 68% based on the AUC0-128 h. Elimination data were also presented 
for commercial phenylbutazone preparations in horses (intravenous 6 mg/kg bw; t1/2 = 6.2 hours). 
32.  In  cattle  treated  with  7.8  mg  phenylbutazone/kg  bw  (commercial  formulation  containing 
ramifenazone), the highest tissue concentrations 8 hours after dosing were detected in plasma, edible 
tissues contained relatively lower residue concentrations (1.4 mg/kg in liver and 1.3 mg/kg in kidney). 
33.  In  healthy  and  leukaemia  virus  infected  cattle  the  elimination  half-lives  (t1/2)  following 
intravenous  and  oral  administration  of  2  x  5  mg  phenylbutazone/kg  bw  were  31.4  to  78.2  hours 
(healthy to infected) and 36.8 to 78.2 hours (healthy to infected) respectively. 
34.  In cattle dosed twice with 5 mg/kg bw with a 3 week interval between doses, the variation in 
plasma  concentrations  with  time  fitted  a  three  compartment  open  model  and  indicated  a  mean 
bioavailability of 68%. In cattle treated with 7.8 mg phenylbutazone/kg bw (commercial formulation 
containing  ramifenazone),  the  area  under  the  curve  was  5221  mg.h/l.  Plasma  protein  binding  of 
phenylbutazone was found to be greater than 90% in all species tested.  
 35.  The majority of the 45 pharmacokinetic studies presented by the applicants were extracted 
from the published literature. None of the studies presented were compliant with the requirements of 
GLP. The pharmacokinetic studies were performed using commercial preparations of phenylbutazone 
containing other pharmacologically active compounds (ramifenazone and/or dexamethasone), or used 
isopropylantipyrine (a compound closely related to phenylbutazone making critical comparison of the 
data impossible. When the target species were dosed with phenylbutazone the major metabolites in 
plasma and urine samples were phenylbutazone and oxyphenbutazone (by HPLC or GLC).  
36.  When  pigs  were  intramuscularly  dosed  21  mg  phenylbutazone/kg  bw  with  a  commercial 
phenylbutazone  preparation  (containing  ramifenazone  and  dexamethasone),  all  tissues  at  6,  8  and 
10 day  timepoints  contained  residue  concentrations  of  phenylbutazone,  oxyphenbutazone  and 
ramifenazone  below  500  µg/kg  (the  analytical  limit  of  detection).  Other  possible  metabolites  of 
phenylbutazone  were  not assayed  for and residue  concentrations  in injection site tissues  were  not 
measured. The study did not comply with the requirements of Volume VI of the Rules Governing 
Medicinal Products in the European Community in terms of the number of animals per time point. 
37.  In a pony 6 hours after oral dosing with 4.4 mg phenylbutazone/kg bw phenylbutazone and 
oxyphenbutazone concentrations were 700 µg/kg and 200 µg/kg respectively in liver, 700 µg/kg and 
1100  µg/kg  respectively  in  kidney  and  100  µg/kg  and  100  µg/kg  respectively  in  muscle. 
Phenylbutazone and oxyphenbutazone residue concentrations in a pony killed 24 hours after dosing 
were 200 µg/kg and less than 100 µg/kg respectively in liver, 400 µg/kg and 400 µg/kg respectively in 
kidney  and  less  than  100  µg/kg  and  less  than  100  µg/kg  respectively  in  muscle.  Plasma  residue 
concentrations  over  the  same  time  period  fell  from  3.3  µg/ml  and  1.1  µg/ml  respectively  to 
0.600 µg/ml and 0.2 µg/ml respectively. No results for residue concentrations in the fat tissues of 
ponies after dosing with phenylbutazone were presented. Higher residues were found in a study in 
horses with one animal slaughtered per time point; however the dosage regime for this study was not 
given.  
38.  When cows were intravenously injected with 7.5 mg phenylbutazone/kg bw, phenylbutazone 
concentrations  in  biopsy  samples  of  liver  and  muscle  were  highest  (8400  µg/kg  and  5600  µg/kg 
respectively) 7 hours after dosing (second timepoint). These concentrations depleted to below the limit 
of detection (less than 50 µg/kg actual value not given) by 392 hours (ca. 17 days) after dosing. No 
kidney or fat samples were analysed. In another study using intravenous injection of 7.8 mg/kg bw 
phenylbutazone  (+  14.4  mg/kg  bw  metamizole)  and  2  animals  per  time  point  residues  of 
phenylbutazone in liver and kidney were 1420 and 1380 µg/kg, 192 hours after dosing and less than Phenylbutazone in horse meat  
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500 and 800 µg/kg 240 hours after dosing. Residues in fat samples were below 500 µg/kg (the limit of 
detection).  None  of  the  cattle  studied  complied  with  the  requirements  of  Volume  VI  in  terms  of 
numbers of animals per time point.  
39.  In  6  lactating  cows  1  hour  after  intravenous  dosing  7.8  mg  phenylbutazone/kg  bw  mean 
residue concentrations of phenylbutazone and oxyphenbutazone in milk were 5 µg/kg and 64 µg/kg 
respectively.  These  concentrations  had  depleted  to  below  the  limit  of  detection  (5  µg/kg)  in  all 
samples by 24 hours for phenylbutazone and 48 hours for oxyphenbutazone. 
40.  None of the residue depletion studies presented meet the requirements of Volume VI. It was 
not possible to assess the suitability of phenylbutazone or phenylbutazone+oxyphenbutazone as the 
marker residue in food producing species due to the lack of data. The ratio of these marker residues to 
total tissue residue was not known for any of the target species. Additionally, metabolism data in rats 
and humans suggest that phenylbutazone residues represent only a very minor fraction (less than 5%) 
of  urinary  residues  and  that  metabolites  such  as  p-γ-dihydroxyphenylbutazone  or 
γ-hydroxyphenylbutazone  could  be  better  choices  for  a  marker  residue.  Furthermore,  there  was 
evidence of rapid phenylbutazone degradation in muscle tissue homogenates. 
41.  A  number  of  analytical  methods  were  provided  for  the  determination  of  residues  of 
phenylbutazone or phenylbutazone+oxyphenybutazone as the marker residue in sample matrices from 
food producing species. Most methods were based on HPLC. None of the methods was validated in 
accordance with the requirements of Volume VI. 
Conclusions 
Having considered that no information was provided in answer to the list of questions regarding: 
  the pharmacological and toxicological NOELs, 
  the submission of adequate reproduction toxicity and teratogenicity studies, 
  the submission of adequate mutagenicity studies, 
  the  mechanism  of  the  carcinogenic  potential  of  phenylbutazone  observed  in  laboratory 
animals, 
  the  aetiology  for  the  blood  dyscrasias  observed  in  humans  arising  from  clinical  use  of 
phenylbutazone and a threshold level for these effects, 
  radiometric studies demonstrating residue depletion and the ratio of marker residue to total 
residue, 
  the choice of the marker residue, 
  a routine analytical method for monitoring purposes, 
and that no ADI could be established and therefore no MRLs could be elaborated, 
the Committee for Veterinary Medicinal Products concluded that a recommendation for the inclusion 
of phenylbutazone into any of the annexes of Council Regulation (EEC) No 2377/90 cannot be made. 
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Appendix B.   Exposure assessment 
B1.  Phenylbutazone in horse samples 
Data from National Residue Control Plans 
The  EU  Member  States  (MS)  routinely  monitor  residues  of  veterinary  medicinal  product  in  live 
animals  and  animal  products  under  the  provision  of  the  Council  Directive  96/23/EC
6.  In  this 
framework, most of the MS ((22/27) are looking for phenylbutazone in horse samples as part of their 
National Residue Control Plans (NRCP); the few countries that are not monitoring phenylbutazone 
producing less than 3 % of the total EU horse production.  
Results  from the NRCP of 19 Member States were collated in the framework of this scientific 
statement, representing a total of 2  386  samples  taken  from  years  2005  to  2013  (Table  B1).  The 
samples were mostly taken at the slaughterhouse. Different matrices were tested: kidney and liver 
(1 171  samples),  muscle  (672  samples),  serum  and  plasma  (475  samples),  other  (milk,  urine:  10 
samples). Overall, 37 samples (1.6 %) were found positive for phenylbutazone. Kidney was the matrix 
with both the highest detection rate (2.9 % corresponding to 33 out of 1 160 kidney samples) and 
highest levels measured: from traces up to 1 900 µg/kg, with a median at 4.0 µg/kg. Two samples of 
plasma and serum (0.4 %) were found positive for phenylbutazone with levels at 3 and 6.5 µg/kg. 
Only one sample of muscle out of 672 (0.1 %) was found positive, with phenylbutazone at 19.2 µg/kg.  
A limitation  of this  dataset  is represented by the  high  inconsistency present both in the analysed 
matrices and the sampling strategies. In particular it is noted that the presence of phenylbutazone is 
monitored  in  different  matrices  including  kidney, liver, serum, plasma and  muscle. Regarding the 
sampling strategy, a substantial variability of the sample proportion was observed among different 
Member States with in some cases an extremely low number of samples. Finally, some differences of 
around a factor 10 were observed in the limits of quantification or CCalpha reported for the different 
matrices. 
In addition to these data, it has to be pointed out that in the framework of their NRCP, some countries 
have also found phenylbutazone in beef samples. The EFSA reports on the results from the monitoring 
of veterinary medicinal product residues and other substances in live animals and animal products 
mention that 17 beef samples were found positive to phenylbutazone during the 2009 – 2011 period 
(EFSA, 2011a, 2012, 2013).  
Information from the Rapid Alert System for Food and Feed (RASFF) 
The presence of phenylbutazone has also been notified to the Rapid Alert System for Food and Feed 
(RASFF) in horse products imported into the European Union (EU). In 2012, phenylbutazone was 
found by the Canadian authorities at 10 µg/kg in kidney and 1.3 µg/kg in muscle tissue of a horse, for 
which some derived products have been imported into the EU (RASFF notification n°2012.1078).      
The presence of phenylbutazone has been reported in frozen beef burgers and meatballs taken from the 
market in Portugal at levels of 2 and 11 µg/kg. These samples were also found positive for horse DNA 
but quantification gave less than 1 % of horse DNA (RASFF notification n°2013.0445).     
  
 
 
                                                   
6  Council Directive 96/23/EC of 29 April 1996 on measures to monitor certain substances and residues thereof in live 
animals  and  animal  products  and  repealing  Directives  85/358/EEC  and  86/469/EEC  and  Decisions  89/87/EEC  and 
91/664/EEC. OJ L 125, 23.5.96, p. 10-32. Phenylbutazone in horse meat  
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Table B1: Results from the monitoring of phenylbutazone in horse samples throughout Europe. 
Member State 
Average 
annual 
production
(a) 
Monitoring 
period 
Total number              
of samples 
tested 
Total number                        
of positive 
samples (%) 
Matrices analysed  Analytical 
technique 
LOQ or 
CCalpha 
(µg/kg) 
Quantified values (µg/kg) 
Austria  943  na  Na  na  Muscle  na  na   
Belgium  12 000  2009-2012  132  0  Muscle  LC-MS/MS  2 - 10   
Bulgaria  2 667  2011  8  0  Muscle  na  11.3   
Cyprus  6 800  -*  -*  -*  -*  -*  -*   
Czech Republic  305  2010-2012  24  1 (4.2)  Muscle  HPLC-MS  2.5  19.2  
Denmark  2 454  2008-2012  33  1 (3.0)  Plasma  LC-MS/MS, 
HPLC-DAD  2 - 13.6  3  
Estonia  0  -*  -*  -*  -*  -*  -*   
Finland  1 102  2008-2012  30  0  Muscle  LC-MS/MS  3.2   
France  16 446  2008-2012  329  0  Muscle  LC-MS/MS  0.92   
Germany  9 109  2005-2012  188  1 (0.5)  Liver, plasma, serum, 
muscle, kidney, milk, urine  na  na  8.2 (liver) 
Greece  0  -*  -*  -*  -*  -*  -*   
Hungary  173  2010-2012  3  0  Liver, muscle, plasma  na  na   
Ireland  4 291  2005-2012  361  1 (0.3)  Kidney  na  5  10  
Italy  94 375  2009-2011  47  0  Plasma  na  na   
Latvia  418  2010-2012  7  0  Muscle  na  na   
Lithuania  2 205  na  na  na  Muscle  na  na   
Luxembourg  0  -*  -*  -*  -*  -*  -*   
Malta  131  na  Na  na  Kidney  na  na   
The Netherlands  1 992  2005-2012  36  0  Muscle  na  na   
Poland  43 651  2009-2011  92  0  Muscle  na  3.8   
Portugal  1 044  2010-2012  9  0  Muscle  na  na   
Romania  20 651  2011  2  0  Muscle  na  1.66   
Slovakia  11  -*  -*  -*  -*  -*  -*   
Slovenia  1 494  2010-2012  6  0  Plasma  na  26   
Spain  28 562  2008-2012  58  0  Muscle  na  na   
Sweden  3 724  2010-2012  225  1 (0.4)  Serum  LC-MS/MS  2.5  6.5  
United Kingdom  4 175  2009-2013  796  32 (4.0)  Kidney  na  na 
Traces x5, 0.84, 1.0x2, 1.1x2, 1.4, 1.6, 
2.0, 2.3, 2.5, 2.8, 3.8, 4.1, 4.9, 5, 5.3, 
6.4, 6.5, 8, 8.2, 10, 12, 49, 110, 1200x2, 
1900  
European Union  303 067    2 386  37 (1.6)         
na: data not available; LC-MS/MS: liquid chromatography – tandem mass spectrometry; HPLC: high performance liquid chromatography; MS: mass spectrometry; DAD: diode array detection; 
LOQ: limit of quantification. 
(a):  annual production: average number of animals produced during the period 2008-2010 (EFSA, 2011a, 2012, 2013). *: Phenylbutazone not tested in horse meat. Phenylbutazone in horse meat  
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B2.  Oxyphenbutazone in horse samples 
This metabolite of phenylbutazone is monitored by some MS in the framework of their NRCP. The 
EFSA reports on the results from the monitoring of veterinary medicinal product residues and other 
substances  in  live  animals  and  animal  products  mention  eight  positive  samples  found  during  the 
2009-2011 period  (EFSA, 2011a, 2012, 2013). Seven  of them  were corresponding to horse blood 
taken  in  live animals  during a local competition  in  Belgium  in 2010 and  were not  considered as 
relevant for the analysis. The last sample corresponded to horse muscle taken in Czech Republic in 
2011. Oxyphenbutazone and phenylbutazone were respectively found at 57.1 and 19.3 µg/kg in that 
sample.       
B3.  Data on the presence of horse meat in beef products 
Two  analytical  techniques  are  currently  available  to  identify  and  quantify  meat  species:  the 
polymerase chain reaction (PCR), which is based on the detection and quantification of horse DNA, 
and  the  Enzyme-Linked  Immunosorbent  Assay  (ELISA),  which  is  based  on  the  detection  and 
quantification of horse proteins. In the further paragraphs, the term ‘horse meat’ used without further 
details refers either to horse DNA or horse proteins. Moreover, the percentage of equine DNA relative 
to bovine DNA is considered equivalent to the percentage of horse meat related to the total meat 
content. According to the European Commission Recommendation (2013/99/EU)
7, a working limit of 
1  %  undeclared  ‘horse  meat’  in  a  food  containing  beef  triggers  further  investigation  of  possible 
adulteration. Indeed, levels below this working limit might result from cross-contamination. Some 
results were reported according to such working limit whereas some others were reported in regards to 
the limit of detection/quantification.  
B3.1.  Results from industry tests 
According to the third summary report on results of industry testing of meat products published by the 
UK FSA on the 1st March 2013, around 1 % of the beef-based products tested (44/4 196 samples) 
contained more than 1 % horse meat (UK-FSA, 2013a). Horse meat was not found in other (non-beef) 
meat  products  (223  samples  tested).  The  beef  based  products  found  positive  for  horse  meat 
corresponded  to:  pasta  with  meat  (lasagne,  tortellini,  etc...),  meat  sauce  (sauce  Bolognese),  meat 
burgers, minced/ground beef meat. 
According to the reports of industry tests for horse meat published by the Food Safety Authority of 
Ireland on the 1st and 25th March 2013, horse meat was found above 1 % in 31 out of 1 856 (1.7 %) 
beef-based products tested (FSAI, 2013a,b). The beef-based products found positive corresponded to 
pasta with meat (lasagne, spaghetti Bolognese), beef burgers and meatballs, meatloaf and cottage pie. 
Horse meat was found to represent up to 30 % of the meat content in burgers, up to 100 % of the meat 
content in pasta with meat (FSAI, 2013c,d) and up to 5.2 % of the meat content in the other products. 
Horse meat was not found in beef meat ingredients (429 samples tested). 
B3.2.  Results from Member States surveys  
The preliminary results of the UK FSA’s UK wide survey of beef products, as published by the UK 
FSA on the 26
th of March 2013 (UK-FSA, 2013b), aimed to be representative of the products available 
across UK, showed that 2 samples out of 362 were found to contain horse DNA above 1 %. At the 
time of the publication, three samples were still undergoing further investigations, as their results were 
disputed by the food business or manufacturer. The two positive samples corresponded to meat burger 
and meat balls. 
 
                                                   
7  Commission Recommendation of 19 February 2013 on a coordinated control plan with a view to establish the prevalence 
of fraudulent practices in the marketing of certain foods. OJ L 48, 21.2.2013, p. 28-32. Phenylbutazone in horse meat  
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B3.3  Information from the Rapid Alert System for Food and Feed  
On the 15
th March 2013, 37 notifications of adulteration of beef based products with horse meat were 
received by the RASFF originating from 13 MS. Around one quarter of the notifications corresponded 
to pasta with meat. The other beef-based products found positive more than once were meat burgers, 
meat balls, beef goulash, beef stewed and frozen pieces of beef. The presence of horse meat was also 
notified in sauce Bolognese, chilli con carne, corned beef, canned beef, cottage pie, beef wraps, beef 
kebab, minced beef and frozen sausage. The percentage of horse meat measured represented up to 
90 % of the meat content in burgers and meatballs, 80 % of the meat stewed, 100 % of the meat 
content in pasta with meat and 70 % of the meat content in the other beef based products.  
B4.  Consumption data of horse and beef based products  
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database) is a 
source of information on food consumption across the European Union (EFSA, 2011b). It gathers 
detailed data originated from 32 national food consumption surveys representing 66 492 individuals of 
22 EU Member States covering all age groups (infant, toddlers, other children, adolescents, adults, 
elderly, very elderly). 
B4.1.  Consumption habits of horse products 
The consumption levels available for horse meat are detailed for the different countries and age groups 
in the Table B2.  
Consumption of horse meat and/or horse meat products (sausages, preserved meat) was reported in 
9 out of 22 countries: France, Italy, Belgium, Sweden, Spain, the Netherlands, Germany, Slovenia and 
Slovakia. Whatever the country and the age class considered, the number of consumers of horse meat 
was very low: less than 10 individuals in 20 population groups, between 11 and 53 individuals in 
8 population  groups.  The  maximum  percentage  of  horse  meat  consumers  estimated  across  the 
population groups was estimated to be approximately 3 %.  
From the surveys with at least 7 reporting days, the frequency of horse meat consumption among the 
consumers  only  was  estimated  to  be  on  average  approximately  1.5  times  per  week,  with  a 
95
th percentile of two times per week. 
From the surveys with at least 5 horse meat consumption events (i.e. days of horse meat consumption), 
the  average  daily  portion  size  ranged  across  the  population  groups  between  16.9  and  85.5  g  for 
children up to 10 years old and between 30.9 to 152.4 g for adults. Due to the very low number of 
consumption  events,  the  high  daily  portion  size  consumed  –  i.e.  95
th  percentile  –  could  be 
characterised only for French and Italian adults at 200.0 g (N = 61 consuming days) and 252.0 g 
(N = 60 consuming days) respectively. 
No consumption event of horse offal was reported in the Comprehensive Database. It is assumed that 
horse offal would not be consumed as such in Europe or at very infrequent occasions.  
 Phenylbutazone in horse meat  
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Table B2: Horse meat consumption data from the Comprehensive Database. 
Dietary survey  Country  Number of 
individuals 
Number of 
horse meat 
consumers 
(%) 
Number   
of 
reporting 
days 
Average 
frequency of 
horse meat 
consumption 
per week (P95) 
Number of 
consuming 
days 
Daily portion size 
Average  P95 
g  g/kg b.w.  g  g/kg 
b.w. 
Toddlers ((≥ 1 year to < 3 years old) 
Regional_Flanders  Belgium  36  1 (2.8)  3  -  1  -  -  -  - 
NUTRICHILD  Bulgaria  428  0 (0)  -  -  -  -  -  -  - 
DIPP  Finland  500  0 (0)  -  -  -  -  -  -  - 
DONALD 2006, 2007, 2008  Germany  261  0 (0)  -  -  -  -  -  -  - 
INRAN_SCAI_2005_06  Italy  36  0 (0)  -  -  -  -  -  -  - 
VCP_kids  The Netherlands  322  0 (0)  -  -  -  -  -  -  - 
IZZ_FAO_2000  Poland  79  0 (0)  -  -  -  -  -  -  - 
enKid  Spain  17  0 (0)  -  -  -  -  -  -  - 
Other children (≥ 3 years to < 10 years old) 
Regional_Flanders  Belgium  625  8 (1.3)  3  -  8  67.3  3.9  -  - 
NUTRICHILD  Bulgaria  434  0 (0)  -  -  -  -  -  -  - 
SISP04  Czech Republic  389  0 (0)  -  -  -  -  -  -  - 
Danish_Dietary_Survey  Denmark  490  0 (0)  -  -  -  -  -  -  - 
DIPP, STRIP  Finland  1 183  0 (0)  -  -  -  -  -  -  - 
INCA2  France  482  9 (1.9)  7  1.2 (-)  11  85.5  3.8  -  - 
DONALD 2006, 2007, 2008  Germany  660  0 (0)  -  -  -  -  -  -  - 
Regional_Crete  Greece  847  0 (0)  -  -  -  -  -  -  - 
INRAN_SCAI_2005_06  Italy  193  1 (0.5)  3  -  1  -  -  -  - 
EFSA_TEST  Latvia  190  0 (0)  -  -  -  -  -  -  - 
VCP_kids  The Netherlands  957  2 (0.2)  2  -  2  -  -  -  - 
IZZ_FAO_2000  Poland  409  0 (0)  -  -  -  -  -  -  - 
NUT_INK05  Spain  399  2 (0.5)  2  -  3  -  -  -  - 
enKid  Spain  156  1 (0.6)  2  -  1  -  -  -  - 
NFA  Sweden  1 473  15 (1.0)  4  -  18  16.9  0.8  -  - 
Adolescents (≥ 10 years to < 18 years old) 
Diet_National_2004  Belgium  611  6 (1.0)  2  -  6  144.8  2.6  -  - 
NSFIN  Bulgaria  162  0 (0)  -  -  -  -  -  -  - 
Childhealth  Cyprus  303  0 (0)  -  -  -  -  -  -  - 
SISP04  Czech Republic  298  0 (0)  -  -  -  -  -  -  - 
Danish_Dietary_Survey  Denmark  479  0 (0)  -  -  -  -  -  -  - Phenylbutazone in horse meat  
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Table B2: Continued. 
Dietary survey  Country  Number of 
individuals 
Number of 
horse meat 
consumers 
(%) 
Number   
of 
reporting 
days 
Average 
frequency of 
horse meat 
consumption 
per week (P95) 
Number of 
consuming 
days 
Daily portion size 
Average  P95 
g  g/kg b.w.  g  g/kg b.w. 
INCA2  France  973  21 (2.2)  7  1.2 (-)  26  130.8  2.6  -  - 
National_Nutrition_Survey_II  Germany  1 011  0 (0)  -  -  -  -  -  -  - 
INRAN_SCAI_2005_06  Italy  247  7 (2.8)  3  -  7  118.1  2.4  -  - 
EFSA_TEST  Latvia  496  0 (0)  -  -  -  -  -  -  - 
IZZ_FAO_2000  Poland  666  0 (0)  -  -  -  -  -  -  - 
NUT_INK05  Spain  651  1 (0.2)  2  -  1  -  -  -  - 
enKid  Spain  209  2 (1.0)  2  -  2  -  -  -  - 
AESAN_FIAB  Spain  86  0 (0)  -  -  -  -  -  -  - 
NFA  Sweden  1 018  9 (0.9)  4  -  13  30.9  0.9  -  - 
Adults (≥ 18 years to < 65 years old) 
ASNS  Austria  2 123  0 (0)  -  -  -  -  -  -  - 
Diet_National_2004  Belgium  1 356  16 (1.2)  2  -  18  152.4  1.9  -  - 
NSFIN  Bulgaria  691  0 (0)  -  -  -  -  -  -  - 
SISP04  Czech Republic  1 666  0 (0)  -  -  -  -  -  -  - 
Danish_Dietary_Survey  Denmark  2 822  0 (0)  -  -  -  -  -  -  - 
NDS_1997  Estonia  1 866  0 (0)  -  -  -  -  -  -  - 
FINDIET_2007  Finland  1 575  0 (0)  -  -  -  -  -  -  - 
INCA2  France  2 276  52 (2.3)  7  1.2 (2.2)  61  139.3  2.0  200.0  3.5 
National_Nutrition_Survey_II  Germany  10 419  12 (0.1)  2  -  12  118.5  1.3  -  - 
National_Repr_Surv  Hungary  1 074  0 (0)  -  -  -  -  -  -  - 
NSIFCS  Ireland  958  0 (0)  -  -  -  -  -  -  - 
INRAN_SCAI_2005_06  Italy  2 313  57 (2.5)  3  -  60  122.6  1.7  252.0  3.7 
EFSA_TEST  Latvia  1 384  0 (0)  -  -  -  -  -  -  - 
DNFCS_2003  The Netherlands  750  2 (0.3)  2  -  2  -  -  -  - 
IZZ_FAO_2000  Poland  2 527  0 (0)  -  -  -  -  -  -  - 
SK_MON_2008  Slovakia  2 761  1 (0.0)  1  -  1  -  -  -  - 
CRP_2008  Slovenia  407  1 (0.2)  1  -  1  -  -  -  - 
AESAN, AESAN-FIAB  Spain  1 391  0 (0)  -  -  -  -  -  -  - 
Riksmaten_1997_98  Sweden  1 210  8 (0.7)  7  1.6  13  40.0  0.6  -  - 
NDNS  United Kingdom  1 724  0 (0)  -  -  -  -  -  -  - 
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Table B2: Continued. 
Dietary survey  Country  Number of 
individuals 
Number of 
horse meat 
consumers 
(%) 
Number   
of 
reporting 
days 
Average 
frequency of 
horse meat 
consumption 
per week (P95) 
Number of 
consuming 
days 
Daily portion size 
Average  P95 
g  g/kg b.w.  g  g/kg 
b.w. 
Elderly (≥ 65 years to < 75 years old) 
Diet_National_2004  Belgium  534  11 (2.1)  2  -  12  86.6  1.2  -  - 
NSFIN  Bulgaria  151  0 (0)  -  -  -  -  -  -  - 
Danish_Dietary_Survey  Denmark  309  0 (0)  -  -  -  -  -  -  - 
FINDIET_2007  Finland  463  0 (0)  -  -  -  -  -  -  - 
INCA2  France  264  8 (3.0)  7  1.0  8  134.4  1.9  -  - 
National_Nutrition_Survey_II  Germany  2 006  2 (0.1)  2  -  -  -  -  -  - 
National_Repr_Surv  Hungary  206  0 (0)  -  -  -  -  -  -  - 
INRAN_SCAI_2005_06  Italy  290  11 (3.8)  3  -  15  73.8  1.0  -  - 
IZZ_FAO_2000  Poland  329  0 (0)  -  -  -  -  -  -  - 
Very elderly (≥ 75 years old) 
Diet_National_2004  Belgium  744  8 (1.1)  2  -  9  126.6  1.9  -  - 
NSFIN  Bulgaria  200  0 (0)  -  -  -  -  -  -  - 
Danish_Dietary_Survey  Denmark  20  0 (0)  -  -  -  -  -  -  - 
INCA2  France  84  0 (0)  -  -  -  -  -  -  - 
National_Nutrition_Survey_II  Germany  490  0 (0)  -  -  -  -  -  -  - 
National_Repr_Surv  Hungary  80  0 (0)  -  -  -  -  -  -  - 
INRAN_SCAI_2005_06  Italy  228  4 (1.8)  3  -  4  94.3  1.7  -  - 
IZZ_FAO_2000  Poland  124  0 (0)  -  -  -  -  -  -  - 
P95: 95
th percentile; b.w.: body weight. 
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B4.2.  Consumption habits of beef-based products 
Consumption  of beef-based products (pasta filled  with  meat, meat burgers and balls, minced beef 
meat, beef canned, beef corned, beef goulash, beef kebab, beef loaf, beef stewed, beef sausage, meat 
pie,  sauce  Bolognese  and  chilli  con  carne)  was  reported  in  almost  all  countries  (21/22  countries) 
(Table B3). The percentage of consumers of beef-based products was higher in the groups of children 
and adolescents (up to 92 % consumers according to the survey) than among the groups of adults and 
elderly (up to 65 % consumers according to the survey).  
From the surveys with at least 7 reporting days, the frequency of beef-based products consumption 
among consumers only was estimated on average around 2 times per week, and at the 95
th percentile 
around 4 times per week. 
Table B4 summarizes the daily portion sizes estimated for the meat content of different beef-based 
products. In the children population groups, the highest portion sizes corresponded to meat burgers 
and meat balls (80 % meat), which ranged across the population group on average between 33.2 and 
142.4 g and between 84.0 and 224.0 g for the 95
th percentile. In the adult population groups, the 
highest average portion sizes corresponded to beef stewed (80 %  meat),  which ranged across the 
population  groups  between  43.1  and  203.8  g.  The  highest  high  (95
th  percentile)  portion  sizes 
corresponded to minced/ground beef meat (100 % meat), which ranged between 129.6 and 300.0 g. 
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Table B3: Number of consumers and frequency of consumption of beef-based products in the Comprehensive database. 
Dietary survey  Country  Number of 
individuals 
Number of beef 
products
(a) consumers 
(%) 
Number of 
reporting days 
Average frequency of beef products 
consumption per week (P95) 
Toddlers ((≥ 1 year to < 3 years old) 
Regional_Flanders  Belgium  36  27 (75.0)  3  - 
NUTRICHILD  Bulgaria  428  125 (29.2)  -  - 
DIPP  Finland  500  242 (48.4)  3  - 
DONALD 2006, 2007, 2008  Germany  261  73 (28.0)  3  - 
INRAN_SCAI_2005_06  Italy  36  1 (2.8)  3  - 
VCP_kids  The Netherlands  322  120 (37.3)  2  - 
IZZ_FAO_2000  Poland  79  29 (36.7)  -  - 
enKid  Spain  17  1 (5.9)  -  - 
Other children (≥ 3 years to < 10 years old) 
Regional_Flanders  Belgium  625  454 (72.6.9)  3  - 
NUTRICHILD  Bulgaria  434  133 (30.6)  -  - 
SISP04  Czech Republic  389  56 (14.4)  2  - 
Danish_Dietary_Survey  Denmark  490  0 (0)  -  - 
DIPP  Finland  948  698 (73.6)  3  - 
STRIP  Finland  250  230 (92.0)  4   
INCA2  France  482  389 (80.7)  7  2.0 (4.0) 
DONALD 2006, 2007, 2008  Germany  660  200 (30.3)  3  - 
Regional_Crete  Greece  847  372 (43.9)  3  - 
INRAN_SCAI_2005_06  Italy  193  6 (3.1)  3  - 
EFSA_TEST  Latvia  190  58 (30.5)  2  - 
VCP_kids  The Netherlands  957  309 (32.3)  2  - 
IZZ_FAO_2000  Poland  409  120 (29.3)  -  - 
NUT_INK05  Spain  399  5 (1.3)  2  - 
enKid  Spain  156  34 (21.8)  2  - 
NFA  Sweden  1 473  1,318 (89.5)  4  - 
Adolescents (≥ 10 years to < 18 years old) 
Diet_National_2004  Belgium  611  270 (44.2)  2  - 
NSFIN  Bulgaria  162  33 (20.4)  -  - 
Childhealth  Cyprus  303  143 (47.2.0)  3  - Phenylbutazone in horse meat  
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Table B3: Continued. 
Dietary survey  Country  Number of 
individuals 
Number of beef 
products
(a) consumers 
(%) 
Number of 
reporting days 
Average frequency of beef products 
consumption per week (P95) 
SISP04  Czech Republic  298  54 (18.1.7)  2  - 
Danish_Dietary_Survey  Denmark  479  0 (0)  -  - 
INCA2  France  973  773 (79.4)  7  2.0 (4.0) 
National_Nutrition_Survey_II  Germany  1 011  334 (33.0)  2  - 
INRAN_SCAI_2005_06  Italy  247  18 (7.3)  3  - 
EFSA_TEST  Latvia  496  121 (24.4)  2  - 
IZZ_FAO_2000  Poland  666  236 (35.4)  -  - 
NUT_INK05  Spain  651  39 (18.7)  2  - 
enKid  Spain  209  12 (5.7)  2  - 
AESAN_FIAB  Spain  86  41 (47.7)  3  - 
NFA  Sweden  1 018  874 (85.9)  4  - 
Adults (≥ 18 years to < 65 years old) 
ASNS  Austria  2 123  308 (14.5)  1  - 
Diet_National_2004  Belgium  1 356  497 (36.7)  2  - 
NSFIN  Bulgaria  691  116 (16.8)  -  - 
SISP04  Czech Republic  1 666  239 (14.3)  2  - 
Danish_Dietary_Survey  Denmark  2 822  0 (0)  -  - 
NDS_1997  Estonia  1 866  444 (23.8)  1  - 
FINDIET_2007  Finland  1 575  615 (39.0)  2  - 
INCA2  France  2 276  1 480 (65.0)  7  1.9 (4.0) 
National_Nutrition_Survey_II  Germany  10 419  2 999 (28.8)  2  - 
National_Repr_Surv  Hungary  1 074  37 (3.4)  3  - 
NSIFCS  Ireland  958  528 (55.1)  7  1.8 (4.0) 
INRAN_SCAI_2005_06  Italy  2 313  101 (4.4)  3  - 
EFSA_TEST  Latvia  1 384  270 (19.5)  2  - 
DNFCS_2003  The Netherlands  750  313 (41.7)  2  - 
IZZ_FAO_2000  Poland  2 527  1 044 (41.3)  -  - 
SK_MON_2008  Slovakia  2 761  176 (6.4)  1  - 
CRP_2008  Slovenia  407  3 (0.7)  1  - 
AESAN  Spain  418  126 (30.1)  2  - 
AESAN-FIAB  Spain  982  424 (43.2)  3  - Phenylbutazone in horse meat  
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Table B3: Continued. 
Dietary survey  Country  Number of 
individuals 
Number of beef 
products
(a) consumers 
(%) 
Number of 
reporting days 
Average frequency of beef products 
consumption per week (P95) 
Riksmaten_1997_98  Sweden  1 210  651 (53.8)  7  1.6 (4.0) 
NDNS  United Kingdom  1 724  989 (57.4)  7  1.9 (4.0) 
Elderly (≥ 65 years to < 75 years old) 
Diet_National_2004  Belgium  534  137 (25.7)  2  - 
NSFIN  Bulgaria  151  12 (7.9)  -  - 
Danish_Dietary_Survey  Denmark  309  0 (0)  -  - 
FINDIET_2007  Finland  463  122 (26.3)  2  - 
INCA2  France  264  101 (38.3)  7  1.6 (3.0) 
National_Nutrition_Survey_II  Germany  2 006  487 (24.3)  2  - 
National_Repr_Surv  Hungary  206  1 (0.5)  3  - 
INRAN_SCAI_2005_06  Italy  290  16 (5.5)  3  - 
IZZ_FAO_2000  Poland  329  114 (34.7)  -  - 
Very elderly (≥ 75 years old) 
Diet_National_2004  Belgium  712  172 (23.1)  2  - 
NSFIN  Bulgaria  200  12 (6.0)  -  - 
Danish_Dietary_Survey  Denmark  20  0 (0)  -  - 
INCA2  France  84  37 (44.0)  7  1.4 (2.4) 
National_Nutrition_Survey_II  Germany  490  108 (22.0)  2  - 
National_Repr_Surv  Hungary  80  1 (1.3)  -  - 
INRAN_SCAI_2005_06  Italy  228  13 (5.7)  3  - 
IZZ_FAO_2000  Poland  124  32 (25.8)  -  - 
P95: 95
th percentile. 
(a):  the beef-based products taken into account are those for which the presence of horse meat has been notified at least once at the European level: pasta filled with meat, meat burgers and 
balls, minced beef meat, beef canned, beef corned, beef goulash, beef kebab, beef loaf, beef stewed, beef sausage, meat pie, sauce Bolognese and chilli con carne.  
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Table B4: Range of daily portion sizes of beef meat contained in beef-based products estimated from the Comprehensive database. 
Beef products 
Children (up to 10 years old)  Adults (from 10 years old) 
Average  P95  Average  P95 
N  g  g/kg b.w.  N  g  g/kg b.w.  N  g  g/kg b.w.  N  g  g/kg b.w. 
Beef canned  -  -  -  -  -  -  5  43.4 – 144.2  0.8 – 1.6  -  -  - 
Beef goulash  1  42.6   1.8  -  -  -  7  46.7 – 109.7  0.8 – 1.5  2  147.4 – 202.9  2.1 – 2.6 
Beef kebab  -  -  -  -  -  -  2  117.1 – 159.1  2.3  -  -  - 
Beef loaf  2  53.9 – 58.4  1.8 – 2.2        2  52.4 – 57.8  0.7 – 0.8       
Beef sausage  3  37.7 – 43.9  1.6 – 3.5  2  100.0 – 118.8  5.6 – 6.5  21  24.8 – 131.3  0.3 – 1.9  8  91.0 – 240.0  1.2 – 3.6 
Beef stewed  3  48.6 – 95.6  2.0 – 3.9  1  120.0  4.8  12  43.1 – 203.8  0.6 – 2.8  3  138.0 – 190.0  2.2 – 3.5 
Chilli con carne  -  -  -  -  -  -  1  103.4  1.5  -  -  - 
Corned beef  -  -  -  -  -  -  5  18.8 – 77.6  0.3 – 1.0  3  91.0 – 172.0  1.1 – 2.1 
Meat burger  11  41.4 – 142.4  2.4 – 5.7  3  90.4 – 168.0  5.0 – 6.2  24  45.0 – 154.7  0.9 – 2.6  9  95.2 – 288.0  1.7 – 5.3 
Meat pie  1  64.5  2.4        3  61.7 – 98.2  0.8 – 2.7  -  -  - 
Meat balls  13  33.2 – 98.3  1.7 – 4.5  4  84.0 – 224.0  3.9 – 9.1  13  51.7 – 132.7  0.8 – 2.4  4  120.0 – 200.0  1.8 – 4.2 
Minced/grounded beef  18  17.2 – 87.7  1.5 – 3.9  10  79.0 – 165.0  4.1 – 7.9  31  57.8 – 155.1  0.7 – 2.4  22  129.6 – 300.0  1.7 – 4.8 
Pasta with meat  5  19.8 – 43.6  0.7 – 2.0  3  60.0 – 90.0  2.3 – 3.9  14  17.8 – 46.5  0.3 – 0.9  4  59.3 – 75.0  1.0 – 1.6 
Sauce bolognese  4  4.2 – 22.2   0.1 – 2.8  1  40.0   1.7  7  16.8 – 51.7  0.3 – 0.7  6  30.0 – 102.4  0.5 – 1.3 
N = number of population groups; b.w.: body weight; P95: 95
th percentile. 
 
Note that the average daily portion size is derived from at least 5 consumption events in a survey, and the 95
th percentile from at least 60 consumption events in a survey. The cooked beef meat 
was estimated to represent 15 % of pasta filled with meat (i.e. lasagne, tortellini), 20 % of meat sauce, 80 % of meat burgers, meat balls and meat loaf, 40 % of beef kebab, beef stewed, beef 
goulash, meat pie and chilli con carne, 100 % of minced/grounded meat, beef sausage, beef canned, beef corned.  
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B5.  Likelihood of dietary exposure to phenylbutazone 
The  likelihood  of  dietary  exposure  to  phenylbutazone  was  estimated  at  the  consumer  level  by 
combining the frequency of consumption of horse meat or beef-based products potentially adulterated 
with horse meat with the prevalence of phenylbutazone in horse meat. An estimate of the number of 
individuals per 100 million potentially exposed each day to phenylbutazone was then derived at the 
population level by combining the likelihood of exposure at the individual level together with the 
estimated  number  of  consumers  of  horse  meat  or  beef  meat  products  within  the  population. 
Calculations were done for each subgroup of population (country x age class combinations) with at 
least  one  consumer.  Taking  the  uncertainty  around  the  input  parameters  into  account,  different 
scenarios were considered (Table B5): 
-  Prevalence of phenylbutazone in horse meat: at 0.13 % and 3.5 %. In absence of data related to the 
presence of phenylbutazone in horse meat as available on the EU market, the results from the 
NRCP  on  the  presence  of  phenylbutazone  in  horse  carcasses  produced  in  Europe  were  used. 
Considering that in the framework of the global European market, a positive horse sample found at 
the production level in one country may have been associated with horse meat products found in 
the market of other countries, one single estimate was determined in order to represent the whole 
European market. 0.13 % corresponds to the average between the percentages of positive samples 
observed  in  the  different  countries  weighted  by  the  average  annual  production  in  the 
corresponding  countries (Table B1). This scenario relies  on the  idea the results  of the NRCP 
provide a true picture on the percentage of positive samples, even for the countries where a very 
low number of samples have been tested in regards to their production levels. A statistical analysis 
performed in order to assess the uncertainty around the prevalence of horse carcasses containing 
phenylbutazone  in  the  EU  showed  that  due  to  the  low  number  of  samples  available  in  some 
countries, the prevalence at the EU level would be below 7.2 % with a 95 % confidence level (see 
Appendix D). The UK is among the Member States which reported the highest detection rates of 
phenylbutazone in horse samples in the last years, with a 3.5 % percentage of positive samples 
(17/480) since the beginning of 2013 in the framework of the UK-Food Standards Agency (FSA) 
‘100% testing of horse carcasses’. This prevalence of 3.5 % was retained as a high estimate for the 
EU  prevalence.  This  estimate  was  within  the  uncertainty  range  of  the  statistical  analysis 
performed. 
-  Frequency of consumption: at 1.5 and 2 times a week for horse meat, and 2 and 4 times a week for 
beef-based products, which corresponded to the highest average and 95
th percentile frequency of 
consumption  estimated  among  consumers  only  across  the  surveys  with  at  least  7 days  of 
consumption available in the Comprehensive database. 
-  Prevalence of horse meat in beef products: 0.1 %, 1 % corresponding to the results of the industry 
tests published UK-FSA (UK-FSA, 2013a), and 2 % as a high bounded scenario, extrapolated 
from  the  results  of  the  industry  tests  published  by  FSAI  (FSAI,  2013a,b)  (1.7  %)  and  the 
preliminary  results  of  the  UK-FSA  UK  wide  survey  of  beef  products  which  revealed  up  to 
5 positive samples out of 362 (1.4 %) (UK-FSA, 2013b).  
The estimated likelihood of dietary exposure to phenylbutazone is higher for the consumers of horse 
meat than for the consumers of beef-based products potentially adulterated with horse meat. Based on 
a horse meat consumption frequency of twice a week and a prevalence of phenylbutazone in horse 
meat  at  3.5  %,  a  consumer  would  be  exposed  to  phenylbutazone  once  every  4  months. Using  a 
conservative scenario (beef-based products consumption frequency of four times a week, 2 % of the 
beef-based  products  containing  horse  meat,  3.5  %  (see  Section  3.1)  of  horse  meat  containing 
phenylbutazone), a consumer of beef-based products could be exposed to phenylbutazone once every 
6.8 years. 
At the population level, and across different country and age groups this would represent from up to 
144  to  up  to  approximately  30 300  individuals  per  100  million  potentially  exposed  each  day  to Phenylbutazone in horse meat  
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phenylbutazone through the consumption of horse meat or horse meat products, and from up to 5 to up 
to 36 800 individuals per 100 million through the consumption of beef-based products adulterated with 
horse meat. 
It must be taken into consideration that these estimates are based on the prevalence of fraudulent 
practices as observed during the first quarter of 2013, which is expected to decrease with time. 
Table B5:  Likelihood of dietary exposure to phenylbutazone. 
 
Expected frequency of exposure 
Years
 (a)  Individuals per 
100 million
(b)  Years
 (a)  Individuals per 
100 million
(b) 
With a prevalence of 
phenylbutazone in horse meat 
of 0.13 %
(c) 
With a prevalence of 
phenylbutazone in horse 
meat of 3.5 %
(d) 
From the consumption of horse meat          
  1.5 times a week   9.8  5 - 844   0.4   144 – 22 727 
  2 times a week  7.4  7 – 1 126   0.3  192 – 30 303 
From the consumption of beef-based 
products          
  2 times a week with a prevalence 
of  horse  meat  in  beef-based 
products of: 
       
0.1 %  7 376  0.2 – 34   274.0  5 – 920  
1.0 %  737.6   2 – 342   27.4  49 – 9 200  
2.0 %  368.8   4 – 683    13.7  97 – 18 400 
  4 times a week with a prevalence 
of  horse  meat  in  beef-based 
products of: 
       
0.1 %  3 688   0.4 – 68  137.0   10 – 1 840  
1.0 %  368.8   4 – 683  13.7   97 – 18 400  
2.0 %  184.4   7 – 1 367   6.8   194 – 36 800  
 (a): Period of time expressed in years within which a consumer could be exposed at least once to a product containing 
phenylbutazone.   
(b):  Range of individuals per 100 million is the minimum – maximum number of individuals per 100 million estimated to be 
exposed each day to a product containing phenylbutazone across the population groups taken into account (N = 28 for 
horse products and N = 76 for beef products). The population groups taken into account are described in Sections B4.1 
and B4.2 of this Appendix. 
(c):  0.13 % is the average percentage of horse samples positive to phenylbutazone weighted according to the production 
level of each country estimated from the results of the National Residue Control Plan (Table B1). 
(d):  3.5 % is the percentage of horse sample positive to phenylbutazone found in the UK during the first months of 2013, 
particularly in the framework of the ‘100 % testing of horse carcasses’. 
  
B6.  Levels of exposure to phenylbutazone 
Considering the  likelihood  of  exposure to  phenylbutazone, only  infrequent events  of  exposure are 
foreseen  at  the  individual  level  for  both  horse  meat  consumers  and  for  consumers  of  beef-based 
products adulterated with horse meat. For this reason, the estimation of chronic exposure levels were 
not  considered  relevant  and  only  the  acute  levels  resulting  from  a  single  day  of  exposure  were 
estimated.  The  highest  portion  sizes  expressed  relatively  to  the  body  weight  observed  among 
population groups with at least 5 consumption events for the average and 60 consumption events for 
the 95
th percentile were retained (Tables B2 and B4). Concerning the beef-based products, only the 
meat burgers/balls, minced/ground beef meat and beef stewed were considered as they were associated 
with the highest portion sizes. It was assumed that respectively 90 %, 80 % and 30 % of the meat 
content  of  meat  burgers/balls,  beef  stewed  and  minced/ground  beef  meat  was  horse  meat, 
corresponding to the highest percentage of horse meat found in the industry tests published by the UK-Phenylbutazone in horse meat  
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FSA, FSAI or notified to the RASFF. Considering the uncertainty around the levels of phenylbutazone 
in horse meat, two scenarios were considered: 
-  A : As a high bounding case scenario, the highest level of phenylbutazone found to date in a 
kidney sample was considered (1900 µg/kg), assuming that levels found in kidney could also 
be found in horse muscle or that meat products could also be adulterated with horse offal.   
-  B:  In  another  scenario,  the  highest  level  of  phenylbutazone  reported  to  date  in  a  muscle 
sample of horse was considered (19.2 µg/kg).  
Table B7:   Acute dietary exposure level to phenylbutazone. 
  Children (up to 10 years)
  Adolescents and adults 
(above 10 years) 
Average  P95  Average  P95 
Scenario A: residue level of 1900 µg/kg  
From horse products consumption         
  Horse meat  7.22  -*  3.61  7.03 
From beef products consumption:          
  Meat burgers/balls (90 % horse 
meat)  9.69  15.55  4.42  9.00 
  Beef stewed (80 % horse meat)  5.92  7.30  4.27  5.38 
  Minced/ground beef meat (30 % 
horse meat)  2.24  4.50  1.38  2.74 
Scenario B: residue level of 19.2 µg/kg  
From horse products consumption         
  Horse meat  0.07  -*  0.04  0.07 
From beef products consumption:          
  Meat burgers/balls (90 % horse 
meat)  0.10  0.16  0.04  0.09 
  Beef stewed (80 % horse meat)  0.06  0.07  0.04  0.05 
  Minced/ground beef meat (30 % 
horse meat) 
0.02  0.05  0.01  0.03 
P95: 95
th percentile. 
*: not enough data available to derive a large portion size of horse meat for children.  
 
The acute levels of exposure were higher in children than in adolescents and in adults (Table B7). 
Assuming  exposure  via horse  meat contaminated at the  highest levels  measured  in  horse samples 
(1900 µg/kg phenylbutazone measured in kidney), the average acute exposure from the consumption 
of horse meat or adulterated beef-based products was estimated to range across the population groups 
from 2.24 to 9.69 µg/kg b.w. per day for children and from 1.38 to 4.42 µg/kg b.w. per day for 
adolescents  and  adults.  The  95
th  percentile  acute  exposure  was  estimated  to  range  across  the 
population groups from 4.50 to 15.55 µg/kg b.w. per day for children, and from 2.74 to 9.00 µg/kg 
b.w. per day in adolescents and adults. When considering horse meat containing phenylbutazone at a 
level equal to that measured in the only positive muscle sample reported (19.2 µg/kg), average acute 
exposure levels ranging from 0.02 to 0.10 µg/kg b.w. per day for children and from 0.01 to 0.04 µg/kg 
b.w. per day for adolescents and adults were estimated. The 95
th percentage acute exposure levels were 
estimated to range from 0.05 to 0.16 µg/kg b.w. per day for children, and from 0.03 to 0.09 µg/kg b.w. 
per day for adolescents and adults. Phenylbutazone in horse meat  
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Appendix C.   Estimation  of  combined  likelihood  for  an  individual  to  be  both  a  subject 
susceptible to develop aplastic anaemia and to be exposed to phenylbutazone from consumption 
of horse meat  
Table C1:  Combined likelihood was calculated considering the likelihood of dietary exposure (see 
Appendix B, Table B5) to be exposed and the likelihood to be a subject susceptible to aplastic anaemia 
(1:30 000). 
  Likelihood of dietary 
exposure 
 
  Individuals per 100 
million 
  Combined likelihood 
From the consumption of horse meat      
  1.5 times a week   144 – 22 727  4.8 x10
-11 – 7.58 x10
-9 
  2 times a week  192 – 30 303  6.4 x10
-11 - 1.01 x10
-8 
From the consumption of beef-based 
products      
  2 times a week with a prevalence of 
horse meat in beef-based products of:   
 
0.1 %  5 – 920   1.67 x10
-12 - 3.07 x10
-10 
1.0 %  49 – 9 200   1.63 x10
-11 - 3.07 x10
-9 
2.0 %  97 – 18 400  3.23 x10
-11 - 6.13 x10
-9 
  4 times a week with a prevalence of 
horse meat in beef-based products of: 
   
0.1 %  10 – 1 840   3.33 x10
-12 - 6.13 x10
-10 
1.0 %  97 – 18 400   3.23 x10
-11 - 6.13 x10
-9 
2.0 %  194 – 36 800   6.47 x10
-11 - 1.23 x10
-8 
 
 Phenylbutazone in horse meat  
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Appendix D.   Sources of uncertainty 
The evaluation of the inherent uncertainties in the assessment of exposure to phenylbutazone has been 
performed following the guidance of the Opinion of the Scientific Committee related to Uncertainties 
in  Dietary  Exposure  Assessment  (EFSA,  2006).  In  addition,  the  report  on  ‘Characterizing  and 
Communicating Uncertainty in Exposure Assessment’ has been considered (WHO-IPCS, 2008).  
The  prevalence  and  levels  of  exposure  were  estimated  on  the  ground  of  the  available  datasets 
generated by the EU Member States in the context of the  National Residue Control Plans. Those 
monitoring programmes are designed for enforcement purposes and not with the aim of estimating the 
exposure for consumers. In this respect several uncertainties were identified, namely: 
-  Some  monitoring  programmes  may  be  designed  to  target  suspect  samples,  leading  to  a 
potential overestimation of the prevalence. 
-  In addition, a low number of samples were taken in some countries with high production of 
horse meat, bringing a considerable uncertainty in the estimation of the parameters of interest.  
o  All results were taken into account to estimate the prevalence, independently from the 
matrices analysed. It was assumed that if phenylbutazone was found in a matrix other than 
muscle, then  it  might  have been also present in  muscle. Nevertheless, considering the 
pharmacokinetic profile of phenylbutazone in horses, the substance is expected to be most 
frequently found and at higher levels in kidney than in muscle. This may have led to an 
overestimation of the prevalence of phenylbutazone in horse meat.      
o  A quantitative uncertainty analysis was conducted through a Bayesian approach which 
indicated that the true prevalence of contaminated carcasses out of the total throughput at 
EU level would be below 7.2 % with a 95 % confidence interval (see paragraph D2). 
However, assuming 3.5 % of the horse meat present in the EU market being positive to 
phenylbutazone was considered as a high bounding scenario (see Annex B).  
o  The acute  exposure  was assessed based on scenarios considering the  highest levels  of 
phenylbutazone  measured  up-to-date.  A  high  percentile  of  contamination,  such  as  the 
95
th percentile,  is  usually  preferred,  as  it  is  more  stable  and  less  biased  by  potential 
outliers. Nevertheless, for both kidney and muscle, the 95
th percentile of contamination 
was  falling  into  the  left  censored  area  (not  detected  results).  This  is  considered  as  a 
conservative scenario. 
The prevalence of fraudulent practices consisting in replacing beef meat by horse meat in beef-based 
products  is  currently  unknown.  Different  scenarios  were  set,  based  on  the  results  available  from 
industry tests in UK and Ireland, and preliminary results from the UK-FSA survey, which showed 
between 1 and 2 % of beef-based products samples tested positive to horse meat. This is considered as 
a conservative estimate, as the positive samples were withdrawn from the market. Moreover, it is not 
known whether horse offal would also enter the food chain illicitly. An exposure scenario considering 
the levels of phenylbutazone found in horse kidney was considered.      
Based on the highest rate of horse meat found to date in beef-based products, it was considered that 
90 % of meat present in beef burgers and meat balls, 80 % of the meat present in beef stewed and 
30 %  of  the  minced/grounded  beef  meat  corresponded  to  horse  meat.  This  is  considered  as  a 
conservative estimate.  
The EFSA Comprehensive European Food Consumption Database does not cover all the European 
population (some Member States/age groups, particularly for children are missing). The consumption 
surveys are usually covering 1 up to 7 days of reporting, and hence they are of limited reliability for 
the characterisation of levels and frequency of consumption of rarely consumed foods, such as horse Phenylbutazone in horse meat  
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meat. Different frequencies of consumption were simulated. A frequency of two consumption events 
per week was assumed as conservative for horse meat consumers. 
In  the  EFSA  Comprehensive  Database,  the  kind  of  meat  present  in  a  meat  product  is  not 
systematically  specified.  Except  for  meat  pie,  pasta  with  meat,  meat  burger,  meatballs  and  sauce 
Bolognese, only the consumption data specifically mentioning the presence of beef meat were taken 
into account. For meat pie, pasta with meat, meat burger, meatballs and sauce Bolognese, both the 
consumption data mentioning the presence of beef meat and meat of unspecified origin were taken 
into account. Moreover, the EFSA Comprehensive Database contains data mostly expressed at the 
ingredients level. For example, in some surveys, beef goulash is reported as a composite dish ‘meat 
goulash’. In that case, the consumption level includes both the meat and other ingredients entering in 
the composition of beef goulash. But in most surveys, the beef part of that composite dish has been 
reported as an ingredient ‘beef  meat’. In that case, the consumption level refers only to the  meat 
content. Some adjustments were made, but this adds uncertainty in the consumption estimates of beef-
based products.  
The exposure scenarios are based on a single ‘European’ estimate, without considering the possible 
variability throughout Europe. As a consequence, the exposure estimates (both likelihood and level) 
produced at a population group level may sometimes be overestimated, sometimes underestimated. 
The  data  available  do  not  allow  describing  the  variability  of  occurrence.  Indeed,  as  the  kind  of 
matrices analysed differs according to the country, it is not possible to distinguish a matrices effect 
from a country effect. Moreover, the results taken into consideration mostly correspond to samples 
taken in slaughterhouses. In the framework of a global European market, this may not reflect the 
occurrence levels in meat present on the each country’s market. 
The exposure scenarios are based on the presence of phenylbutazone in horse meat consumed as such, 
or illicitly present in beef-based products. It must be underlined that phenylbutazone has been reported 
in  bovine  animals  (EFSA,  2011a,  2012,  2013).  This  source  of  exposure  has  not  been  taken  into 
account as such, leading to a potential underestimation of the dietary exposure levels of the European 
population to this substance.   
Because of the lack of data on oxyphenbutazone and on its concurrent presence with phenylbutazone, 
this metabolite has not been taken into consideration in the exposure assessment, which may lead to an 
underestimation of the risk. 
Finally, no information is available on the incidence of aplastic anaemia related to the exposure to 
phenylbutazone at doses in the range of those estimated to occur from the consumption of horse meat 
(approximately 15 µg/kg b.w. per day or below). The incidence of 1 case of aplastic anaemia over 
30 000 subjects, observed in the therapeutic use of the substance at doses typically ranging from 200 
to 400 mg/person per day, was considered for the calculation of the combined likelihood that a subject 
is both sensitive to develop aplastic anaemia and is exposure to phenylbutazone from the consumption 
of horse meat, likely leading to an overestimation of the risk.  
 
D.1.  Quantitative analysis around the prevalence of phenylbutazone in horse carcasses 
A stochastic approach based on binomial process and Bayesian inference principles was applied in 
order to include uncertainty and variability around the parameter of interest. In the specific case, the 
estimation of the prevalence was performed by means of a binomial process. The true underlying 
prevalence was estimated considering the data reported in Table B1 and assuming a Beta probabilistic 
distribution with an uninformative prior (considering the number of samples to be not representative of 
the  overall  target  population).  Under  this  approach  the  prevalence  of  horse  carcasses  containing 
phenylbutazone can be expressed as follows: Phenylbutazone in horse meat  
 
EFSA Journal 2013;11(4):3190  43 
 
          (1) 
 
where n is the number of tested samples and s is the number of positive samples. 
Once the underlying prevalence and its uncertainty were calculated, it was possible to estimate, for 
each  country,  the  actual  number  of  positive  carcasses  out  of  the  total  throughput.  The  overall 
prevalence, i.e. the prevalence of positive carcasses at EU level, could then be estimated as follows: 
 
        (2) 
where m is the number of reporting countries, Cases is the estimated number of real cases for each 
country and N is the average annual throughput per country. 
Data were stored and managed in Microsoft Excel. The modelling exercise and the simulations were 
performed using the software @Risk
8. The simulation ran 10 000 iterations. 
Results 
Equation (1) was used to estimate the underlying true prevalence at country level. The values of the 
95
th percentile confidence level and the mode are reported in Table D1. 
                                                   
8  @RISK,  Risk  Analysis  Add-In  for  Microsoft  Excel,  Version  5.0.1:  Professional  Edition;  Copyright  2008,  Palisade 
Corporation Phenylbutazone in horse meat  
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Table D1:  Data on sample size (n) and  number of positive tests (s) for each country. The  mode 
represents the most likely value estimated for the prevalence. 95 % represents the 95
th percentile of the 
uncertainty distribution around the prevalence at country level.  
      Prevalence 
Member State  s  n  Mode  95 % 
Belgium  0  132  3.77E-05  0.0223 
Bulgaria  0  8  5.57E-04  0.2830 
Czech Republic  1  24  4.01E-02  0.1761 
Denmark  1  33  3.18E-02  0.1321 
Finland  0  30  1.62E-04  0.0921 
France  0  329  1.52E-05  0.0090 
Germany  1  188  5.59E-03  0.0249 
Hungary  0  3  1.25E-03  0.5270 
Ireland  1  361  2.77E-03  0.0130 
Italy  0  47  1.04E-04  0.0605 
Latvia  0  7  6.27E-04  0.3122 
The Netherlands  0  36  1.36E-04  0.0777 
Poland  0  92  5.39E-05  0.0317 
Portugal  0  9  5.01E-04  0.2588 
Romania  0  2  1.67E-03  0.6315 
Slovenia  0  6  7.17E-04  0.3482 
Spain  0  58  8.51E-05  0.0495 
Sweden  1  225  4.31E-03  0.0208 
United Kingdom  32  796  4.00E-02  0.0536 
SUM  37  2 386     
 
As can be seen from Table D1, the uncertainty around the prevalence at country level is directly 
related to the number of collected samples. 
The underlying prevalence at European level was then estimated using Equation (2). 
The result from a simulation (10 000 iterations) gives the cumulative distribution shown in Figure D1, 
which allows estimating with a 95 % confidence that  the prevalence of horse carcasses containing 
phenylbutazone at EU level is below 7.2 %. 
 
 
Figure D1:  Estimated prevalence of horse carcasses containing phenylbutazone at European Union 
level. It can be stated with a 95 % confidence that the true underlying prevalence is below 7.2 %. 
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ABBREVIATIONS 
 
ADI        Acceptable daily intake 
b.w.        Body weight 
Comprehensive Database  EFSA Comprehensive European Food Consumption Database 
CHMP       EMA Committee for Medicinal Products for Human Use 
CVMP       EMA Committee for Medicinal Products for Veterinary Use 
EFSA        European Food Safety Authority 
ELISA       Enzyme-Linked Immunosorbent Assay 
EMA        European Medicines Agency 
EU        European Union 
FCI        Food Chain Information 
FSAI        Food Safety Authority of Ireland 
HPLC-DAD      High performance liquid chromatography – diode-array  detection 
HPLC-MS      High performance liquid chromatography – mass spectrometry 
LC-MS/MS      Liquid chromatography – tandem mass spectrometry 
LOQ        Limit of quantification 
MRL        Maximum residue limits 
MS        Member State 
NOEL        No-observed-effect level 
NRCP        National Residue Control Plan 
NSAID       Non-steroidal anti-inflammatory drug 
PCR        Polymerase chain reaction 
RASFF       Rapid Alert System for Food and Feed 
UK FSA       United Kingdom Food Standards Agency 
 
 